## Mortality among people who inject drugs: a systematic review and meta-analysis
###### Bradley M Mathers,[a] Louisa Degenhardt,[b] Chiara Bucello,[b] James Lemon,[b] Lucas Wiessing [c] & Mathew Hickman [d]


##### Introduction

People who use drugs, especially by injection, are at higher
risk of dying from both acute and chronic diseases, many of
which are related to their drug use, than people who do not
use these drugs. Fatal overdose and infection with human im­
munodeficiency virus (HIV) and other blood-borne viruses
transmitted through shared needles and syringes are the most
common causes of death in this group.[1] Understanding causes
of death is important when setting priorities for programmes
designed to reduce deaths from the use of drugs. Longitudinal
studies of people who inject drugs are critical for assessing
the magnitude, nature and correlates of the risk of death in
this population.

A systematic review conducted in 2004 identified 30 pro­
spective studies published between 1967 and 2004 that dealt
with “problematic drug users” or people who inject drugs.[2]
These reviews have consistently shown that the practice of
injecting drugs is associated with an elevated risk of death,
particularly from the complications of HIV infection, drug
overdose and suicide. Since these reviews were conducted,
the number of studies examining mortality among cohorts
of people who inject drugs has risen substantially. This has
made it possible to perform fine-grained analyses that were not
feasible in earlier reviews. Furthermore, those earlier reviews
did not examine the potential impact of study-level variables,
variation across countries, or of participant-level variables that
could affect both mortality rates and differences in causes of
death, yet study-level evidence suggests that males who inject
drugs may be at higher risk of dying than females and that
different types of drugs are associated with different risks of

a The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia.


death.[3][–][5] Findings from other reviews have also suggested that
rates of death among people who are dependent on opioids are
different from the rates of death observed in people who are
dependent on stimulants such as cocaine and amphetamine
type stimulants.[3][–][5]

In recent years the number of studies reporting on mor­
tality among people who inject drugs has increased. Hence,
the objective of this review was to determine the following:

- overall crude mortality rates (CMRs) and excess deaths

across cohorts of people who inject drugs, by sex;

- causes of death across studies, particularly from drug over­

dose and acquired immunodeficiency syndrome (AIDS);
differences in mortality rates and causes of death among
HIV-positive (HIV+) and HIV-negative (HIV−) people
who inject drugs;

- differences in mortality rates across cohorts by geographi­

cal location and country income level;

- mortality rates by type of drug injected (e.g. opioids versus

stimulants);

- mortality rates during in-treatment and off-treatment

periods.

##### Methods

###### Identifying studies

A recent series of reviews identified cohort studies among opi­
oid, amphetamine and cocaine users to examine mortality.[3][–][5] In
these reviews tailored search strings were used to search three
electronic databases for studies published between 1980 and


b National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.

c Scientific Division, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal.

d School of Social and Community Medicine, University of Bristol, Bristol, England.
Correspondence to Bradley M Mathers (e-mail: bmathers@kirby.unsw.edu.au).
(Submitted: 31 May 2012 – Revised version received: 26 November 2012 – Accepted: 28 November 2012 )


-----

y y g p p j g


2012: Medline, EMBASE and PsycINFO.
The search strings contained keywords
and database-specific terms (MeSH
headings, EMTREE terms and explode
terms; Box 1). All results were limited
to human subjects. We identified grey
literature sources reporting on mortality
by searching online grey literature data­
bases, library databases and the web sites
listed in a published technical report.[6] To
make sure that no relevant papers had
been missed, we sent the draft lists of the
papers identified through these searches
to experts for their review.

For the current study we exam­
ined all papers found in the reviews of
drug-related mortality but selected only
cohorts composed of people who in­
jected opioids and other drugs. We used
the strategy outlined in the preceding
paragraph to further search for these

Box 1. Strategy for search of the peer-reviewed literature

**( < opioids > OR < cocaine > OR**

**Medline:**

longitudinal studies/ OR exp follow-up studies/ OR exp prospective studies/)
**EMBASE:**

longitudinal study/ OR exp prospective study/ OR exp follow up/)
**PsychINFO:**

Note: $ indicates wildcard.


cohorts. We included in the analysis
only studies of drug users that included
mortality data disaggregated by partici­
pants’ injecting drug use; studies were
included only if more than 70% of the
cohort was composed of people who
injected drugs.

The searches yielded a total of 5981
studies of mortality related to the use of
opioids, amphetamines and cocaine. We
identified another 79 articles by search­
ing the reference lists of reviews on mor­
tality related to drug use. Experts pro­
vided additional studies for 16 cohorts.
From these 5981 articles we excluded a
total of 5762: 4999 did not focus on drug
dependence or mortality, 118 did not
include raw data, 292 were case series,
and 600 had insufficient mortality data
on people who inject drugs. In total, we
selected 67 cohort studies for inclusion


in the analyses (Fig. 1). These studies
were further assessed using STROBE
reporting guidelines.[7]

###### Data extraction

Once we had identified all studies, one
of the authors (JL) extracted the data
into an Excel database (Microsoft, Red­
mond, United States of America) and
two others rechecked them (BM, CB).
This yielded the basic data set for the
statistical analyses. We extracted infor­
mation on the location of each study, the
period of recruitment and duration of
follow-up, the number of people in the
cohort, the percentage of people in the
cohort who injected drugs, the number
of person–years (PY) of follow-up and
the number of deaths.

We extracted CMRs and standard­
ized mortality ratios (SMRs). We ex­


-----

o ta ty a o g peop e o ject d ugs y


Fig. 1. **Flowchart showing study selection process for systematic review of studies on**

**mortality in people who inject drugs**

|Col1|Total from initial search|
|---|---|
|||


From experts:
16

|60|60|
|---|---|
|||

|60|76|
|---|---|
|||
|||

|1077|Col2|
|---|---|
|||
|||

|959|Col2|
|---|---|
|||
|||

|667|Col2|
|---|---|
|||
|||


pressed CMRs as the number of deaths
per 100 PY of follow-up. We reported
SMRs as calculated in the source pa­
pers. In several cases standard errors,
confidence intervals (CIs) and CMRs
were not reported, so we estimated them
using standard calculations. We also put
into the database CMRs and SMRs that
were reported according to sex, HIV
status, treatment status and type of drug
injected, as well as data on deaths from
drug overdose or AIDs-related causes.

We included in the analyses studies
that specified treatment status if they
classified the data by mutually exclusive
treatment groups or periods. We only
included studies in which the exact dates
of entry into and exit from the study had
been recorded and used to calculate the


number of PYs, the number of deaths
and mortality rates.

###### Statistical analysis

We performed meta-analyses to estimate
pooled all-cause CMRs and all-cause
SMRs, and pooled estimates of deaths
from specific causes, as in previous re­
views.[8] To perform the meta-analyses we
used the “metan” command in STATA
version 10.1 (StataCorp LP, College Sta­
tion, USA). The “metan” command uses
inverse-variance weighting to calculate
random effects pooled summary esti­
mates and their confidence limits, true
effect differences between studies and
study heterogeneity.[9][,][10] Random effects
models allow for heterogeneity between
and within studies. We expected high


levels of heterogeneity between stud­
ies because of the marked differences
between the samples of people inject­
ing drugs; accordingly, we applied a
random effects model to all analyses.
The appropriateness of this a priori
decision was confirmed by the resultant
_χ[2] and the I-squared statistic. To further_
investigate this heterogeneity, when the
data permitted we divided the cohorts
into subgroups and used CMR ratios to
compare differences in mortality.[11] We
made comparisons between subgroups
as follows: sex (male versus female); pri­
mary drug injected at baseline (opioids
versus stimulants); HIV status (HIV+
versus HIV−); and treatment for drug
dependence (in-treatment period versus
off-treatment period).

We examined the following as po­
tential sources of heterogeneity in CMRs
or SMRs using random effects univariate
meta-regressions in STATA: geographic
region, country income group (based on
World Bank categories), percentage of
sample that injected drugs, were male
or were HIV+ at baseline; presence of
opioid users in the cohort; and the year
in which the follow-up period ended.[12][,][13]

##### Results

We included 67 cohorts in the analysis;
14 were from low- and middle-income
countries (Table 1). Studies from Eu­
rope, North America and Australasia
were the most common; nine studies
were from Asia and one was from South
America. The pooled CMR across the 65
cohorts for which a CMR was provided
was 2.35 deaths per 100 PY (Fig. 2). Co­
horts from Asia had the highest pooled
CMRs (5.25), followed by the cohorts
from North America (2.64) and western
Europe (2.31); cohorts from Australasia
had the lowest pooled CMR (0.71).

SMRs were reported for 31 cohorts;
their pooled SMR was 14.68 (Fig. 3).
Since the heterogeneities (I[2]) of the
pooled CMR and SMR were both very
high (98.6% and 98.3%, respectively), we
stratified estimates by subgroups.

###### Sex differences in mortality

Thirty-seven studies presented CMRs
by sex. [14] [,] [17] [–] [19] [,] [21] [–] [24] [,] [26] [,] [28] [,] [30] [–] [32] [,] [34] [,] [36] [–] [38] [,] [43] [,]

45–50,52,54,57,58,62,66–72,74 The pooled CMR
ratio for males versus females was 1.32
(Fig. 4), which suggests that crude mor­
tality was higher among males. Nineteen
studies reported SMRs by sex;[14][,][17][,][21][,][24][,]

26,28,30,32,34,38,43,46,52,54,58,66,67,70,74 the pooled


-----

y y g p p j g


-----

o ta ty a o g peop e o ject d ugs y


-----

y y g p p j g


-----

o ta ty a o g peop e o ject d ugs y

Fig. 2. **Crude mortality rates for people who inject drugs, by region**


%%

**Weight**


**Cohort**


CMR (95% CI)CMR (95% CI)

|Western Europe Antolini 2006 (Italy) Bargagli 2001 (Italy) Bauer 2008 (Austria) Brancato 1995 (Italy) Ciccolallo 2000 (Italy) Clausen 2008 (Norway) Copeland 2004 (UK) Cornish 2010 (UK) Davoli 2007 (Italy) EMCDDA 2011 (Sweden) Eskild 1993 (Norway) Esteban 2003 (Spain) Frischer 1997 (UK) Fugelstad 1995 (Sweden) Fugelstad 1997 (Sweden) Fugelstad 1998 (Sweden) Galli 1994 (Italy) Goedert 1995 (Italy) Golz 2001 (Germany) Haarr 2007 (Norway) Hickman 2003 (UK) Jarrin 2007 (Spain) Lejckova 2007 (Czech Republic) Lumbreras 2006 (Spain) Manfredi 2006 (Italy) Mezzelani 1998 (Italy) Moroni 1991 (Italy) Muga 2007 (Spain) Nyhlen 2011 (Sweden) Oppenheimer 1994 (UK) Sanchez−Carbonell 2000 (Spain) Seaman 1998 (UK) Sorensen 2005 (Denmark) Stenbacka 2007 (Sweden) VanHaastrecht 1996 (Netherlands) Zabransky 2011 (Czech Republic) Zaccarelli 1994 (Italy) Subtotal (I−squared = 97.4%, p = 0.000) . Asia Azim 2008 (Bangladesh) Azim 2009 (Bangladesh) Jafan 2010 (Islamic Republic of Iran) Liu 2011 (China) Quan 2007 (Thailand) Quan 2010 (Viet Nam) Rahimi-Movahgar 2009 (Islamic Republic of Iran) Solomon 2009 (India) Zhang 2005 (China) Subtotal (I−squared = 74.3%, p = 0.000) . Latin America Cardoso 2006 (Brazil) Subtotal (I−squared = .%, p = .) . Australasia Degenhardt 2009 (Australia) Digusto 2004 (Australia) Reece 2010 (Australia) Stoove 2008 (Australia) Tait 2008 (Australia) Subtotal (I−squared = 89.7%, p = 0.000) . Eastern Europe EMCDDA 2011 (Romania) EMCDDA 2011 (Croatia) EMCDDA 2011 (Bulgaria) EMCDDA 2011 (Latvia) Moskalewicz 1996 (Poland) Subtotal (I−squared = 97.1%, p = 0.000) . North America Evans 2012 (USA) Fingerhood 2006 (USA) Goedert 2001 (USA) McAnulty 1995 (USA) Miller 2007 (Canada) O’Driscoll 2001 (USA) Vlahov 2005 (USA) Vlahov 2008 (USA) Subtotal (I−squared = 99.4%, p = 0.000) . Overall (I−squared = 98.6%, p = 0.000) NOTE: Weights are from random effects analysis|Col2|Col3|22..0011 ((11..7799,, 22..1166)) 11..8833 22..1155 ((22..0055,, 22..2255)) 11..8844 55..4422 ((33..4455,, 77..4400)) 00..7777 22..0044 ((11..2266,, 22..8833)) 11..5511 22..2266 ((22..0088,, 22..4433)) 11..8833 11..9955 ((11..7700,, 22..2233)) 11..8800 22..4455 ((22..0066,, 22..8844)) 11..7755 11..0000 ((00..8866,, 11..1155)) 11..8833 00..7744 ((00..5599,, 00..8888)) 11..8833 33..3333 ((22..9988,, 33..6688)) 11..7777 22..7777 ((22..2222,, 33..4422)) 11..6644 33..6688 ((33..1111,, 44..2255)) 11..6666 22..0088 ((11..5522,, 22..6644)) 11..6666 33..8855 ((22..9944,, 44..7766)) 11..4433 11..9999 ((11..7722,, 22..2255)) 11..8800 77..7766 ((55..5544,, 1100..5588)) 00..5577 22..5522 ((22..2288,, 22..7777)) 11..8811 11..5577 ((11..4411,, 11..7755)) 11..8833 44..2222 ((22..8800,, 55..6644)) 11..0088 11..9922 ((00..9955,, 33..4444)) 11..1199 11..6611 ((11..1133,, 22..2233)) 11..6677 22..0022 ((11..9922,, 22..1122)) 11..8844 00..8844 ((00..7755,, 00..9933)) 11..8844 22..1188 ((22..0000,, 22..3366)) 11..8833 22..0044 ((11..8800,, 22..3300)) 11..8811 22..9911 ((22..4488,, 33..3333)) 11..7744 22..4433 ((22..1166,, 22..6699)) 11..8800 33..7744 ((33..3388,, 44..1144)) 11..7766 11..3300 ((11..1122,, 11..4488)) 11..8833 11..8833 ((11..2288,, 22..3388)) 11..6677 33..4400 ((22..3366,, 44..4444)) 11..3333 22..3333 ((11..6600,, 33..2277)) 11..4488 33..4499 ((22..4455,, 44..5533)) 11..3333 22..1122 ((11..9933,, 22..3311)) 11..8822 33..2233 ((22..5566,, 44..0077)) 11..5544 00..4488 ((00..1155,, 00..8811)) 11..7788 22..3300 ((11..9966,, 22..6633)) 11..7788 22..3311 ((22..0066,, 22..5566)) 6600..2266 66..3322 ((44..6688,, 77..9966)) 00..9944 33..5522 ((22..4466,, 44..5599)) 11..3311 44..0088 ((11..2255,, 66..9911)) 00..4488 66..8899 ((55..7799,, 77..9988)) 11..2299 33..8855 ((22..4422,, 55..8833)) 00..9911 66..3300 ((44..6600,, 88..5500)) 00..7788 44..8833 ((00..0000,, 1144..3300)) 00..1100 44..2255 ((33..3355,, 55..1166)) 11..4433 77..7733 ((44..8877,, 1100..6600)) 00..4477 55..2255 ((44..1166,, 66..3355)) 77..7711 22..7777 ((11..4455,, 44..0099)) 11..1144 22..7777 ((11..4455,, 44..0099)) 11..1144 00..8899 ((00..8866,, 00..9922)) 11..8855 11..2277 ((00..4400,, 22..2299)) 11..4400 00..5500 ((00..3366,, 00..6655)) 11..8833 00..8833 ((00..5566,, 11..2211)) 11..7788 00..5500 ((00..2299,, 00..7722)) 11..8822 00..7711 ((00..4466,, 00..9966)) 88..6688 00..5577 ((00..4477,, 00..6688)) 11..8844 11..0099 ((00..9933,, 11..2255)) 11..8833 11..1188 ((00..9911,, 11..4466)) 11..8800 11..6600 ((11..4433,, 11..7777)) 11..8833 22..2288 ((11..8811,, 22..8833)) 11..6699 11..3311 ((00..8822,, 11..8800)) 88..9999 00..9911 ((00..6622,, 11..2200)) 11..7799 77..1144 ((55..2222,, 99..0066)) 00..8800 44..6677 ((44..4422,, 44..9922)) 11..8811 11..0055 ((00..6699,, 11..4411)) 11..7777 11..3377 ((00..8800,, 11..9944)) 11..6655 11..5599 ((11..2222,, 11..9966)) 11..7766 44..5500 ((44..2244,, 44..7766)) 11..8800 00..7711 ((00..5544,, 00..8888)) 11..8833 22..6644 ((11..2255,, 44..0022)) 1133..2222 22..3355 ((22..1122,, 22..5588)) 110000..0000|Col5|Col6|
|---|---|---|---|---|---|
|||||||


−10 −5 0 5 10 15

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; CMR, crude mortality rate.


-----

y y g p p j g

Fig. 3. **Standardized mortality ratios for people who inject drugs, by region**


%%

**Weight**


**Cohort**


SMR (95% CI)SMR (95% CI))

|Western Europe Antolini 2006 (Italy) Bargagli 2001 (Italy) Bauer 2008 (Austria) Ciccolallo 2000 (Italy) Copeland 2004 (UK) EMCDDA 2011 (Sweden) Eskild 1993 (Norway) Ferri 2007 (Italy) Frischer 1997 (UK) Galli 1994 (Italy) Lejckova 2007 (Czech Republic) Mezzelani 1998 (Italy) Nyhlen 2011 (Sweden) Oppenheimer 1994 (UK) Sanchez−Carbonell 2000 (Spain) Sorensen 2005 (Denmark) Stenbacka 2007 (Sweden) VanHaastrecht 1996 (Netherlands) Zabransky 2011 (Czech Republic) Zaccarelli 1994 (Italy) Subtotal (I−squared = 98.8%, p = 0.000) . Asia Quan 2007 (Thailand) Quan 2010 (Viet Nam) Solomon 2009 (India) Zhang 2005 (China) Subtotal (I−squared = 81.2%, p = 0.001) . Australasia Degenhardt 2009 (Australia) Subtotal (I−squared = .%, p = .) . Eastern Europe EMCDDA 2011 (Romania) EMCDDA 2011 (Croatia) EMCDDA 2011 (Latvia) Moskalewicz 1996 (Poland) Subtotal (I−squared = 87.7%, p = 0.000) . North America McAnulty 1995 (USA) Miller 2007 (Canada) Subtotal (I−squared = 64.4%, p = 0.094) . Overall (I−squared = 98.3%, p = 0.000) NOTE: Weights are from random effects analysis|Col2|1133..0011 ((1111..3388,, 1133..0099)) 44..0088 1177..3300 ((1166..5500,, 1188..2200)) 44..0088 2299..1133 ((1199..2277,, 4444..0044)) 11..2266 3300..7700 ((1177..3300,, 4444..0000)) 11..1133 1177..4455 ((1144..5599,, 2200..3300)) 33..6688 2277..6600 ((2244..9900,, 3300..7700)) 33..6677 3311..0000 ((2244..6600,, 3377..4400)) 22..5577 77..7777 ((66..7700,, 88..9955)) 44..0055 2222..0000 ((1166..5500,, 2288..8800)) 22..6655 2200..5500 ((2200..0022,, 2244..3333)) 33..8866 88..1155 ((77..2288,, 99..0099)) 44..0088 1144..2288 ((1122..2288,, 1166..5566)) 33..8866 55..9944 ((55..5500,, 66..8800)) 44..1100 1111..9900 ((88..6644,, 1166..0099)) 33..4422 2288..5588 ((1144..6655,, 4422..6655)) 11..0066 1155..7755 ((1111..4400,, 2211..2200)) 33..0044 44..3388 ((33..9999,, 44..7788)) 44..1122 2244..8800 ((1199..4411,, 3311..2233)) 22..7722 1144..4400 ((99..3311,, 1199..4499)) 22..9988 3311..9922 ((2277..4444,, 3366..9933)) 33..0099 1177..5522 ((1144..6622,, 2200..4433)) 6633..5511 1133..9900 ((88..7711,, 2211..0044)) 22..6644 1133..4400 ((1111..4400,, 1155..3300)) 33..9911 1111..1100 ((88..8855,, 1133..7700)) 33..8800 4477..6622 ((3311..6633,, 6688..7711)) 00..6688 1144..4477 ((99..9955,, 1199..0000)) 1111..0022 66..4400 ((66..2200,, 66..6600)) 44..1122 66..4400 ((66..2200,, 66..6600)) 44..1122 66..5500 ((55..4400,, 77..7700)) 44..0055 1100..3300 ((88..9900,, 1122..0000)) 33..9988 99..0000 ((88..0000,, 1100..0000)) 44..0077 1122..0066 ((99..6600,, 1155..0000)) 33..7722 99..2255 ((77..2222,, 1111..2288)) 1155..8822 88..3300 ((55..7711,, 1111..6666)) 33..6655 1166..4400 ((99..1100,, 2277..1100)) 11..8888 1111..1199 ((33..5588,, 1188..8800)) 55..5533 1144..6688 ((1133..0011,, 1166..3355)) 110000..0000|Col4|
|---|---|---|---|
|||||


−68.7 0 68.7

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; SMR, standardized mortality ratio.


CMR ratio suggests that females had
significantly greater excess mortality
than males in similar age groups in the
general population (Fig. 5). Only two
of the nineteen studies presented SMRs
for males that were greater than those
for females.[30][,][74]

###### Causes of death

Several studies reported specific causes
of death. The pooled CMR for death
from drug overdose was 0.62 per 100 PY
across 43 studies (Fig. 6). Eleven stud­
ies reported CMRs for death from drug
overdose by sex: overall the CMR was


1.38 times higher (Fig. 7) among males
than among females.[14][,][17][,][19][,][21][,][24][,][32][,][38][,][49][,][52][,][57][,][58]

In 20 studies CMRs were pro­
vided separately for people who inject
drugs according to their HIV sta­
tus.[15][,][16][,][18][,][28][,][34][,][36][–][40][,][45][,][48][,][49][,][55][,][57][,][60][,][65][,][70][,][72][,][74] Allcause mortality was three times higher
among HIV+ than among HIV− sub­
jects (CMR ratio: 3.15) (Fig. 8). Much
of this elevated mortality appeared
to result from AIDS deaths among
HIV+ users of injecting drugs. The
pooled estimate of AIDS-related mor­
tality for the 16 studies for which data
were available was 2.55 per 100 PY


(Fig. 9).[28][,][33][–][36][,][38][–][41][,][48][,][49][,][60][,][65][,][70][,][72][,][74] When
we examined mortality from causes
other than AIDS, we found it to be
1.63 times higher among HIV+ than
among HIV− people who inject drugs
(Fig. 10).[28][,][34][,][36][,][38][–][40][,][48][,][49][,][60][,][65][,][70][,][72][,][74]

Mortality from drug overdose was
presented by HIV status in 9 stud­
ies.[28][,][34][,][36][,][38][,][39][,][49][,][65][,][70][,][74] Pooled estimates
showed mortality to be twice as high
among HIV+ than among HIV− people
who inject drugs (CMR ratio: 1.99)
(Fig. 11). Further analyses across 13
studies conducted on HIV+ people
who inject drugs showed no significant


-----

o ta ty a o g peop e o ject d ugs y

Fig. 4. **Ratios of crude mortality rates in males versus females who inject drugs**


**%%**

**Weight**


**Cohort**


RR (95% CIRR (95% CI)

|Antolini 2006 (Italy) Bargagli 2001 (Italy) Bauer 2008 (Austria) Brancato 1995 (Italy) Ciccolallo 2000 (Italy) Clausen 2008 (Norway) Copeland 2004 (UK) Cornish 2010 (UK) Degenhardt 2009 (Australia) EMCDDA 2011 (Croatia) Eskild 1993 (Norway) Evans 2012 (USA) Ferri 2007 (Italy) Frischer 1997 (UK) Fugelstad 1997 (Sweden) Fugelstad 1998 (Sweden) Galli 1994 (Italy) Hickman 2003 (UK) Jarrin 2007 (Spain) Lejckova 2007 (Czech Republic) Liu 2011 (China) Lumbreras 2006 (Spain) Manfredi 2006 (Italy) McAnulty 1995 (USA) Miller 2007 (Canada) Moskalewicz 1996 (Poland) O’Driscoll 2001 (USA) Oppenheimer 1994 (UK) Reece 2010 (Australia) Sorensen 2005 (Denmark) Stenbacka 2007 (Sweden) Stoove 2008 (Australia) Tait 2008 (Australia) VanHaastrecht 1996 (Netherlands) Vlahov 2005 (USA) Vlahov 2008 (USA) Zaccarelli 1994 (Italy) Overall (I−squared = 63.9%, p = 0.000) NOTE: Weights are from random effects analysis|Col2|11..3300 ((11..0099,, 11..5555)) 44..9988 00..9977 ((00..8866,, 11..0099)) 55..6633 22..6622 ((11..1188,, 55..8811)) 11..0011 11..1144 ((00..4444,, 33..0011)) 00..7722 11..3322 ((11..0099,, 11..6611)) 44..7766 11..1144 ((00..8855,, 11..5533)) 33..6688 11..2233 ((00..8877,, 11..7744)) 33..1133 11..6677 ((11..1166,, 22..4400)) 22..9999 11..5588 ((11..4477,, 11..7700)) 66..0033 22..5577 ((11..5566,, 44..2244)) 22..0055 11..0088 ((00..7700,, 11..6677)) 22..4444 11..6600 ((00..7766,, 33..3377)) 11..1122 11..5511 ((11..0066,, 22..1166)) 33..0066 00..9999 ((00..5577,, 11..7722)) 11..7777 11..3355 ((00..9999,, 11..8844)) 33..5522 11..7744 ((00..9933,, 33..2266)) 11..4488 11..1144 ((00..8899,, 11..4455)) 44..1199 22..0011 ((00..7788,, 55..1188)) 00..7755 11..3366 ((11..1199,, 11..5555)) 55..5500 11..8888 ((11..4444,, 22..4455)) 33..9955 00..8800 ((00..3399,, 11..6666)) 11..1177 11..5500 ((11..2211,, 11..8866)) 44..5566 11..1144 ((00..8866,, 11..5511)) 33..7777 11..5599 ((00..6666,, 33..8844)) 00..8855 00..6644 ((00..2277,, 11..5533)) 00..8888 11..8800 ((11..0000,, 33..2233)) 11..6633 11..1100 ((00..6688,, 11..7788)) 22..1155 00..8866 ((00..4455,, 11..6644)) 11..4411 33..3311 ((11..3311,, 88..3366)) 00..7777 00..6688 ((00..3377,, 11..2244)) 11..5588 11..2244 ((00..9988,, 11..5566)) 44..3355 33..4499 ((11..3322,, 99..2222)) 00..7711 11..0099 ((00..4433,, 22..7766)) 00..7777 11..4422 ((00..8877,, 22..3322)) 22..1111 11..2200 ((11..0044,, 11..3388)) 55..3399 11..2211 ((00..7733,, 11..9999)) 22..0044 11..2222 ((00..8866,, 11..7744)) 33..0099 11..3322 ((11..2211,, 11..4444)) 110000..0000|Col4|Col5|
|---|---|---|---|---|
||||||


.5 1 2 3 4

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; RR, relative risk.


difference in deaths from drug overdose
and from AIDS in this group (CMR
ratio: 1.35; _P = 0.554) (Fig. 12).[28][,][33][–][36][,][38][,]_

39,41,49,65,70,71,74

Only four studies presented data by
sex and HIV status.[37][,][47][,][49][,][74] They showed
no significant difference in CMRs be­
tween HIV+ males and HIV+ females
who inject drugs (CMR ratio: 1.13;
Fig. 13), but HIV– males had a pooled
CMR 1.81 times greater than that of
HIV– females who inject drugs (Fig. 14).

###### Mortality by primary drug injected at baseline

Five studies estimated mortality by
primary drug injected (opioids versus


stimulants) (Table 2). Pooled estimates
of all-cause mortality by primary type
of drug injected showed no overall dif­
ference across studies (CMR ratio: 1.25;
95% CI: 0.60–2.61; _P = 0.553).[36][,][46][,][57][,][70][,][71]_
The same was true of studies of mortal­
ity resulting from drug overdose (CMR
ratio: 1.85; 95% CI: 0.75–4.56; P = 0.18).
In three of the four studies mortality as­
sociated with drug overdose was higher
among people injecting opioids than
among those injecting stimulants.[36][,][46][,][71]
In the fourth study, people who injected
primarily stimulants had higher rates of
drug overdose; however, the deaths from
overdose in this group were later shown to
have been caused by opioid use.[57]


###### Mortality according to treatment

Six studies provided information on
mortality during in-treatment and
off-treatment periods at follow-up: the
meta-analysis suggested that mortality
was 2.52 times higher during off-treat­
ment periods than during in-treatment
periods (Fig. 15).[22][,][23][,][25][,][26][,][35][,][37]

###### Heterogeneity in mortality

We performed univariate analyses to
determine if the heterogeneity in overall
CMRs and SMRs could be explained by
participant characteristics and method­
ological variables. The results showed
that high-income countries had lower


-----

y y g p p j g

Fig. 5. **Ratios of standardized mortality ratios for males versus females who inject drugs**


**%**

|Cohort|Col2|Col3|Weight RR (95% CI)|Col5|
|---|---|---|---|---|
|Antolini 2006 (Italy) Bargagli 2001 (Italy) Ciccolallo 2000 (Italy) Copeland 2004 (UK) Degenhardt 2009 (Australia) EMCDDA 2011 (Croatia) Eskild 1993 (Norway) Ferri 2007 (Italy) Frischer 1997 (UK) Galli 1994 (Italy) Hickman 2003 (UK) Lejckova 2007 (Czech Republic) Miller 2007 (Canada) Moskalewicz 1996 (Poland) Oppenheimer 1994 (UK) Sorensen 2005 (Denmark) Stenbacka 2007 (Sweden) VanHaastrecht 1996 (Netherlands) Zaccarelli 1994 (Italy) Overall (I−squared = 87.3%, p = 0.000) NOTE: Weights are from random effects analysis|||00..6600 ((00..5500,, 00..7711)) 66..9944 00..4411 ((00..3366,, 00..4466)) 77..2244 00..5500 ((00..4411,, 00..6611)) 66..8833 00..6677 ((00..4477,, 00..9955)) 55..7744 00..6688 ((00..6633,, 00..7733)) 77..4400 11..0055 ((00..6644,, 11..7733)) 44..6600 00..4433 ((00..2288,, 00..6677)) 55..0066 00..2299 ((00..2211,, 00..4422)) 55..6688 00..4433 ((00..2255,, 00..7744)) 44..2211 00..3366 ((00..2288,, 00..4466)) 66..5500 00..9955 ((00..3377,, 22..4455)) 22..3300 00..9999 ((00..7766,, 11..2299)) 66..3355 00..2244 ((00..1100,, 00..5577)) 22..6600 00..5555 ((00..3311,, 00..9999)) 44..0000 00..8811 ((00..4422,, 11..5533)) 33..6666 00..3377 ((00..2200,, 00..6677)) 33..9933 00..6600 ((00..4477,, 00..7755)) 66..6600 00..7799 ((00..4499,, 11..2299)) 44..6688 11..4444 ((11..0011,, 22..0055)) 55..7700 00..5588 ((00..4499,, 00..6699)) 110000..0000||
||||||
||||||
||||||
||||||
||||||
||||||


.5 1 1.5

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; RR, relative risk.


CMRs than low- and middle-income
countries (Fig. 16). Cohorts with greater
proportions of males and HIV+ partici­
pants at baseline also had higher CMRs.
Cohorts whose follow-up periods ended
in more recent years had lower SMRs
(Table 3). Study data were not sufficient
to allow for multivariate analyses.

##### Discussion

Although previous reviews have exam­
ined mortality among people who inject
drugs, to our knowledge this is the most
comprehensive systematic review of
the topic and the first to employ novel
approaches to search for the available
evidence. These approaches ranged from
standard searches of the peer-reviewed
literature to comprehensive searches of
the non-peer reviewed literature and
multiple expert consultations, as well
as examination of both participant- and
study-level factors potentially associated
with the risk of death.

The pooled CMR of 2.35 deaths
per 100 PY provides evidence of the


high mortality associated with injecting
drug use. The pooled SMR of 14.68 also
shows that mortality is much higher
in those who inject drugs than in the
general population. Differences by sex
were evident: across all studies that
reported mortality by sex, males had
higher CMRs, yet females who inject
drugs had a much higher elevation in
mortality relative to their age-matched
peers in the general population than did
males who inject drugs.

Most of the cohorts identified were
from 14 high-income countries; togeth­
er these 14 counties represent 78% of
the total estimated population of people
who inject drugs in such countries.[76]
Studies from only 11 low or middle
income countries were identified; these
countries account for only 40% of the
estimated number of people inject­
ing drugs in low- or middle-income
countries.[76]

Although pooled CMRs were
higher among people injecting drugs
in low- and middle-income countries
rather than high-income countries, we


observed no significant difference in
pooled SMRs. This suggests that the
higher CMRs may reflect higher over­
all mortality in the general population
in low- and middle-income countries
than in high-income countries. The
lowest and highest mortality rates were
documented in cohorts in Australasia
and Asia, respectively. Differences across
high-income countries probably reflect
differences in HIV infection prevalence,
coverage of HIV prevention and cov­
erage of opioid agonist maintenance
treatment.[76][,][77]

Drug overdose and AIDS-related
mortality were by far the most com­
mon causes of death. The pooled CMR
for death from drug overdose was 0.62
per 100 PY, higher among males than
females who inject drugs, and higher
among HIV+ people who inject drugs
than among those who were HIV−.
In three of the four studies comparing
drug overdose among people injecting
opioids compared to those injecting
stimulants, CMRs were higher among
the former group, as expected.[36][,][46][,][71] In


-----

o ta ty a o g peop e o ject d ugs y

Fig. 6. **Crude mortality rates for death from drug overdose in people who inject drugs**


%%

**Weight**


**Cohort**


CMR (95% CICMR (95% CI)

|Antolini 2006 (Italy) Bargagli 2001 (Italy) Bauer 2008 (Austria) Brancato 1995 (Italy) Ciccolallo 2000 (Italy) Clausen 2008 (Norway) Copeland 2004 (UK) Davoli 2007 (Italy) Degenhardt 2009 (Australia) Digusto 2004 (Australia) Eskild 1993 (Norway) Ferri 2007 (Italy) Fingerhood 2006 (USA) Frischer 1997 (UK) Fugelstad 1995 (Sweden) Fugelstad 1997 (Sweden) Galli 1994 (Italy) Goedert 1995 (Italy) Goedert 2001 (USA) Haarr 2007 (Norway) Hickman 2003 (UK) Jarrin 2007 (Spain) Lejckova 2007 (Czech Republic) Manfredi 2006 (Italy) McAnulty 1995 (USA) Miller 2007 (Canada) Moroni 1991 (Italy) O’Driscoll 2001 (USA) Oppenheimer 1994 (UK) Quan 2007 (Thailand) Seaman 1998 (UK) Solomon 2009 (India) Stenbacka 2007 (Sweden) Stoove 2008 (Australia) Tait 2008 (Australia) van Haastrecht 1996 (Netherlands) Vlahov 2005 (USA) Vlahov 2008 (USA) Zaccarelli 1994 (Italy) Zhang 2005 (China) Nyhlen 2011 (Sweden) Zabransky 2011 (Czech Republic) Quan 2010 (Viet Nam) Overall (I−squared = 96.2%, p = 0.000) NOTE: Weights are from random effects analysis|Col2|00..6611 ((00..5533,, 00..6699)) 33..2277 00..5522 ((00..4477,, 00..5577)) 33..3322 22..0066 ((00..8844,, 33..2277)) 00..4400 00..8800 ((00..3300,, 11..3300)) 11..5500 00..6699 ((00..6600,, 00..8800)) 33..2211 11..0033 ((00..8844,, 11..2222)) 22..8855 00..6611 ((00..4433,, 00..8833)) 22..7799 00..4400 ((00..0099,, 00..7722)) 22..2244 00..4433 ((00..4411,, 00..4455)) 33..3366 00..7766 ((−−00..1100,, 11..6622)) 00..7711 11..8855 ((11..3377,, 22..3333)) 11..5577 00..4466 ((00..3399,, 00..5566)) 33..2244 00..8811 ((00..3300,, 11..7766)) 00..9911 00..9988 ((00..6633,, 11..4455)) 11..8833 22..3300 ((11..6644,, 33..1100)) 00..9911 00..9977 ((00..7788,, 11..1155)) 22..8888 00..9922 ((00..7777,, 11..0077)) 33..0044 00..3300 ((00..2233,, 00..3377)) 33..2288 00..6644 ((00..5555,, 00..7744)) 33..2222 11..2222 ((00..3322,, 22..1122)) 00..6666 11..0011 ((00..5588,, 11..4444)) 11..7733 00..3322 ((00..2288,, 00..3366)) 33..3344 00..1188 ((00..1144,, 00..2233)) 33..3333 00..4455 ((00..3344,, 00..5566)) 33..1166 00..4411 ((00..2222,, 00..7711)) 22..5588 00..2255 ((00..0077,, 00..6644)) 22..3399 00..9933 ((00..7777,, 11..1122)) 22..9944 00..7700 ((00..4488,, 00..9988)) 22..5544 00..7777 ((00..4466,, 11..2222)) 11..9955 00..8899 ((00..1111,, 11..6677)) 00..8833 11..4411 ((00..8866,, 22..1188)) 11..0066 11..1100 ((00..6644,, 11..5566)) 11..6633 00..0055 ((00..0022,, 00..0088)) 33..3355 00..4444 ((00..2266,, 00..7755)) 22..5588 00..1144 ((00..0033,, 00..2266)) 33..1155 00..7722 ((00..4411,, 11..1177)) 11..9966 00..7711 ((00..6611,, 00..8822)) 33..1199 00..3311 ((00..2211,, 00..4466)) 33..1122 00..5555 ((00..4400,, 00..7744)) 22..9944 44..7711 ((22..5533,, 66..8888)) 00..1144 00..3300 ((00..2222,, 00..3399)) 33..2255 00..1122 ((00..0000,, 00..2299)) 33..0044 11..6699 ((00..7733,, 22..6655)) 00..6600 00..6622 ((00..5533,, 00..7700)) 110000..0000|Col4|Col5|Col6|
|---|---|---|---|---|---|
|||||||


−2 0 2 4 6

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; CMR, crude mortality rate.


a fourth study, however, drug overdose
was higher among people who injected
stimulants,[57] although further inves­
tigation revealed that the deaths from
overdose in this group were more often
linked to the injection of opioids than
to the injection of stimulants. This find­
ing highlights the fact that people who
inject drugs often use more than one
drug type, even if they have a particular
drug of choice.

The prevalence of HIV infection
varied widely. As expected, overall mor­
tality was much higher among HIV+
than among HIV− people who inject
drugs (pooled CMR ratio: 3.15), but


mortality from causes other than AIDS
was also higher among those who were
HIV+. Overdose-related mortality was
also higher among HIV+ people who
inject drugs in many cohorts. These
differences in mortality may reflect dif­
ferences in risky behaviour, physical
health and social disadvantage.

The observational evidence exam­
ined in this review is consistent with the
evidence from randomized controlled
trials that opioid agonist maintenance
treatment is associated with a reduced
risk of death.[78] Among cohorts for which
in-treatment and off-treatment periods
were carefully tracked, mortality rates


were around 2.5 times higher in offtreatment periods than in in-treatment
periods. Variation in exposure to treat­
ment could also explain differences
between cohorts in mortality from drug
overdose, although this variation was
not explicitly measured across cohorts.

The prevention of HIV transmis­
sion among people who inject drugs is
clearly a public health priority.[79][,][80] There
is growing evidence that opioid agonist
maintenance treatment, antiretrovi­
ral treatment and needle and syringe
programmes reduce HIV transmis­
sion.[81][–][83] These interventions have been
implemented in many countries, but


-----

y y g p p j g


often on a limited scale only.[77] Clearly,
however, AIDS is only one of several
common causes of death in this group:
a comprehensive approach to improving
health outcomes among people who
inject drugs must also include efforts to
reduce other causes of death frequently
found among them, particularly drug
overdose.[84]

###### Limitations of the evidence

Evidence on mortality rates among users
of injecting drugs is still predominantly
from high-income countries, particu­
larly in western Europe. Interestingly,
however, this review has shown that
despite marked differences in CMRs
across countries, the extent to which
this mortality exceeds that of the general
population may show less pronounced
differences. It would be inappropriate
to assume that mortality is equally high
among all people who inject drugs. New
research in this area is needed, especially


Fig. 7. **Ratios of crude mortality rates for death from drug overdose in males versus**

**females who inject drugs**


**%**

|Cohort|Col2|Col3|Weight RR (95% CI)|Col5|
|---|---|---|---|---|
|Antolini 2006 (Italy) Bargagli 2001 (Italy) Brancato 1995 (Italy) Ciccolallo 2000 (Italy) Copeland 2004 (UK) Ferri 2007 (Italy) Galli 1994 (Italy) Manfredi 2006 (Italy) Miller 2007 (Canada) O’Driscoll 2001 (USA) Oppenheimer 1994 (UK) Overall (I−squared = 46.5%, p = 0.044) NOTE: Weights are from random effects analysis|||11..8833 ((11..2277,, 22..6644)) 1155..2222 11..4411 ((11..0077,, 11..8855)) 1177..9944 00..6633 ((00..1166,, 22..4400)) 22..8822 11..8844 ((11..2233,, 22..7744)) 1144..2299 11..0055 ((00..5533,, 22..0088)) 88..1166 00..6655 ((00..3366,, 11..1177)) 99..8888 11..0033 ((00..7700,, 11..5544)) 1144..3322 33..0000 ((11..2299,, 66..9977)) 66..0077 33..3366 ((00..3355,, 3322..1199))11..0088 11..4499 ((00..6699,, 33..2222)) 66..9944 11..9911 ((00..5566,, 66..5599)) 33..2277 11..3388 ((11..0088,, 11..7766) 110000..0000||
||||||
||||||
||||||
||||||
||||||
||||||
||||||


.5 1 5

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval, RR, relative risk.


Fig. 8. **Ratios of crude mortality rates in HIV-positive versus HIV-negative people who inject drugs**

**Cohort**

Azim 2008 (Bangladesh)

Azim 2009 (Bangladesh)

Bauer 2008 (Austria)

Eskild 1993 (Norway)

Frischer 1997 (UK)

Fugelstad 1997 (Sweden)

Fugelstad 1998 (Sweden)

Galli 1994 (Italy)

Goedert 1995 (Italy)

Goedert 2001 (USA)

Jarrin 2007 (Spain)

Lumbreras 2006 (Spain)

Manfredi 2006 (Italy)

Muga 2007 (Spain)

O’Driscoll 2001 (USA)

Quan 2010 (Viet Nam)

Solomon 2009 (India)

VanHaastrecht 1996 (Netherlands)

Vlahov 2008 (USA)

Zaccarelli 1994 (Italy)

**Overall (I−squared = 66.8%, p = 0.000)**

NOTE: Weights are from random effects analysis

.5 1 2 4 6

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk.

|Fig. 8. Ratios of crude mortality rates in HIV-positive versus HIV-negative people who inject drugs|Col2|Col3|Col4|Col5|Col6|
|---|---|---|---|---|---|
|% Cohort RR (95% CI) Weight||||||
|Azim 2008 (Bangladesh) Azim 2009 (Bangladesh) Bauer 2008 (Austria) Eskild 1993 (Norway) Frischer 1997 (UK) Fugelstad 1997 (Sweden) Fugelstad 1998 (Sweden) Galli 1994 (Italy) Goedert 1995 (Italy) Goedert 2001 (USA) Jarrin 2007 (Spain) Lumbreras 2006 (Spain) Manfredi 2006 (Italy) Muga 2007 (Spain) O’Driscoll 2001 (USA) Quan 2010 (Viet Nam) Solomon 2009 (India) VanHaastrecht 1996 (Netherlands) Vlahov 2008 (USA) Zaccarelli 1994 (Italy) Overall (I−squared = 66.8%, p = 0.000) NOTE: Weights are from random effects analysis||||44..0088 ((22..2266,, 77..3388)) 33..2233 00..4422 ((00..0066,, 33..0022)) 00..4400 33..3311 ((11..6633,, 66..7700)) 22..5500 22..2244 ((11..4466,, 33..4433)) 44..8866 33..5533 ((11..5555,, 88..0055)) 11..9966 33..7755 ((22..8844,, 44..9955)) 77..0088 11..3388 ((00..7744,, 22..5577)) 33..0000 22..4411 ((11..9988,, 22..9944)) 88..5500 1100..0000 ((55..5599,, 1177..8888)) 33..3322 33..4477 ((33..1111,, 33..8866)) 99..9922 33..3355 ((33..0000,, 33..7755)) 99..8855 33..0022 ((22..5544,, 33..6600)) 88..8899 22..1188 ((11..5588,, 22..9999)) 66..4422 22..9911 ((22..2244,, 33..7777)) 77..4411 22..4488 ((00..9922,, 66..6677)) 11..4444 33..5566 ((22..0044,, 66..2211)) 33..5522 22..9933 ((11..9944,, 44..4444)) 55..0011 33..6622 ((22..2277,, 55..7799)) 44..3377 22..4466 ((11..1188,, 55..1122)) 22..3366 55..3311 ((33..7755,, 77..5533)) 55..9955 33..1155 ((22..7788,, 33..5588)) 110000..0000||
|||||||
|||||||


-----

o ta ty a o g peop e o ject d ugs y

Fig. 9. **Crude mortality rates for AIDS-related deaths in people injecting drugs who were HIV-positive at baseline**

**%**

**Cohort** **CMR (95% CI)**

Eskild 1993 (Norway) 0.62 (0.01, 1.23)0.62 (0.01, 1.23)

Fingerhood 2006 (USA) 3.91 (2.48, 5.33)3.91 (2.48, 5.33)

Frischer 1997 (UK) 3.41 (−0.45, 7.27)3.41 (−0.45, 7.27)

Fugelstad 1995 (Sweden) 0.39 (0.10, 0.68)0.39 (0.10, 0.68)

Fugelstad 1997 (Sweden) 0.48 (0.26, 0.70)0.48 (0.26, 0.70)

Galli 1994 (Italy) 2.97 (2.36, 3.58)2.97 (2.36, 3.58)

Goedert 1995 (Italy) 1.73 (1.43, 2.02)1.73 (1.43, 2.02)

Goedert 2001 (USA) 9.12 (8.13, 10.10)9.12 (8.13, 10.10)

Golz 2001 (Germany) 1.74 (0.83, 2.65)1.74 (0.83, 2.65)

Lumbreras 2006 (Spain) 1.94 (1.69, 2.20)1.94 (1.69, 2.20)

Manfredi 2006 (Italy) 2.73 (2.28, 3.17)2.73 (2.28, 3.17)

Solomon 2009 (India) 3.37 (1.61, 5.14)3.37 (1.61, 5.14)

van Haastrecht 1996 (Netherlands) 1.71 (0.74, 2.68)1.71 (0.74, 2.68)

Vlahov 2008 (USA) 1.24 (0.25, 2.23)1.24 (0.25, 2.23)

Zaccarelli 1994 (Italy) 2.83 (2.25, 3.42)2.83 (2.25, 3.42)

Quan 2010 (Viet Nam) 8.64 (3.94, 13.34)8.64 (3.94, 13.34)

**Overall (I−squared = 96.9%, p = 0.000)** 2.55 (1.81, 3.28)2.55 (1.81, 3.28)

NOTE: Weights are from random effects analysis

−5 0 5 10

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
AIDS, acquired immunodeficiency syndrome; CI, confidence interval; CMR, crude mortality rate; HIV, human immunodeficiency virus.

Fig. 10. Ratios of crude mortality rates for non-AIDS-related deaths in HIV-positive versus HIV-negative people who inject drugs

**%**

**Cohort** **RR (95% CI)**

Eskild 1993 (Norway) 1.96 (1.28, 3.01)1.96 (1.28, 3.01)

Frischer 1997 (UK) 1.77 (0.78, 4.02)1.77 (0.78, 4.02)

Fugelstad 1997 (Sweden) 2.80 (2.12, 3.70)2.80 (2.12, 3.70)

Galli 1994 (Italy) 1.15 (0.94, 1.40)1.15 (0.94, 1.40)

Goedert 1995 (Italy) 3.77 (2.11, 6.74)3.77 (2.11, 6.74)

Goedert 2001 (USA) 1.31 (1.18, 1.46)1.31 (1.18, 1.46)

Lumbreras 2006 (Spain) 1.98 (1.67, 2.36)1.98 (1.67, 2.36)

Manfredi 2006 (Italy) 0.57 (0.42, 0.79)0.57 (0.42, 0.79)

Quan 2010 (Viet Nam) 1.52 (0.87, 2.65)1.52 (0.87, 2.65)

Solomon 2009 (India) 1.83 (1.21, 2.77)1.83 (1.21, 2.77)

VanHaastrecht 1996 (Netherlands) 2.66 (1.66, 4.25)2.66 (1.66, 4.25)

Vlahov 2008 (USA) 0.62 (0.30, 1.29)0.62 (0.30, 1.29)

Zaccarelli 1994 (Italy) 1.96 (1.38, 2.78)1.96 (1.38, 2.78)

**Overall (I−squared = 88.4%, p = 0.000)** 1.63 (1.28, 2.08)1.63 (1.28, 2.08)

NOTE: Weights are from random effects analysis

.5 1 2 3 4

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk.

|Cohort|Col2|Col3|Weight CMR (95% CI) %|Col5|
|---|---|---|---|---|
|Eskild 1993 (Norway) Fingerhood 2006 (USA) Frischer 1997 (UK) Fugelstad 1995 (Sweden) Fugelstad 1997 (Sweden) Galli 1994 (Italy) Goedert 1995 (Italy) Goedert 2001 (USA) Golz 2001 (Germany) Lumbreras 2006 (Spain) Manfredi 2006 (Italy) Solomon 2009 (India) van Haastrecht 1996 (Netherlands) Vlahov 2008 (USA) Zaccarelli 1994 (Italy) Quan 2010 (Viet Nam) Overall (I−squared = 96.9%, p = 0.000) NOTE: Weights are from random effects analysis|||00..6622 ((00..0011,, 11..2233)) 77..1111 33..9911 ((22..4488,, 55..3333)) 55..8844 33..4411 ((−−00..4455,, 77..2277)) 22..4444 00..3399 ((00..1100,, 00..6688)) 77..3388 00..4488 ((00..2266,, 00..7700)) 77..4422 22..9977 ((22..3366,, 33..5588)) 77..1100 11..7733 ((11..4433,, 22..0022)) 77..3388 99..1122 ((88..1133,, 1100..1100)) 66..5599 11..7744 ((00..8833,, 22..6655)) 66..7700 11..9944 ((11..6699,, 22..2200)) 77..4400 22..7733 ((22..2288,, 33..1177)) 77..2277 33..3377 ((11..6611,, 55..1144)) 55..2222 11..7711 ((00..7744,, 22..6688)) 66..6611 11..2244 ((00..2255,, 22..2233)) 66..5577 22..8833 ((22..2255,, 33..4422)) 77..1133 88..6644 ((33..9944,, 1133..3344)) 11..8844 22..5555 ((11..8811,, 33..2288)) 110000..0000||
||||||
||||||

|Cohort|Col2|Col3|) Weight RR (95% CI %|Col5|Col6|
|---|---|---|---|---|---|
|Eskild 1993 (Norway) Frischer 1997 (UK) Fugelstad 1997 (Sweden) Galli 1994 (Italy) Goedert 1995 (Italy) Goedert 2001 (USA) Lumbreras 2006 (Spain) Manfredi 2006 (Italy) Quan 2010 (Viet Nam) Solomon 2009 (India) VanHaastrecht 1996 (Netherlands) Vlahov 2008 (USA) Zaccarelli 1994 (Italy) Overall (I−squared = 88.4%, p = 0.000) NOTE: Weights are from random effects analysis|||11..9966 ((11..2288,, 33..0011)) 77..6655 11..7777 ((00..7788,, 44..0022)) 44..6688 22..8800 ((22..1122,, 33..7700)) 88..8855 11..1155 ((00..9944,, 11..4400)) 99..3388 33..7777 ((22..1111,, 66..7744)) 66..3388 11..3311 ((11..1188,, 11..4466)) 99..8811 11..9988 ((11..6677,, 22..3366)) 99..5511 00..5577 ((00..4422,, 00..7799)) 88..5555 11..5522 ((00..8877,, 22..6655)) 66..5588 11..8833 ((11..2211,, 22..7777)) 77..7755 22..6666 ((11..6666,, 44..2255)) 77..3300 00..6622 ((00..3300,, 11..2299)) 55..2266 11..9966 ((11..3388,, 22..7788)) 88..3311 11..6633 ((11..2288,, 22..0088)) 110000..0000|||
|||||||
|||||||
|||||||


-----

y y g p p j g

Fig. 11. Ratios of crude mortality rates for death from drug overdose in HIV-positive versus HIV-negative people who inject drugs

**%**

**Cohort** **RR (95% CI)** **Weight**

Eskild 1993 (Norway) 2.02 (1.18, 3.45)2.02 (1.18, 3.45) 13.2413.24

Frischer 1997 (UK) 2.41 (0.58, 10.05)2.41 (0.58, 10.05) 5.745.74

Fugelstad 1997 (Sweden) 3.51 (2.33, 5.28)3.51 (2.33, 5.28) 14.5214.52

Galli 1994 (Italy) 1.04 (0.70, 1.56)1.04 (0.70, 1.56) 14.5714.57

Goedert 1995 (Italy) 3.90 (1.36, 11.18)3.90 (1.36, 11.18) 8.228.22

Manfredi 2006 (Italy) 0.77 (0.43, 1.38)0.77 (0.43, 1.38) 12.7512.75

Solomon 2009 (India) 2.18 (0.92, 5.16)2.18 (0.92, 5.16) 9.889.88

VanHaastrecht 1996 (Netherlands) 3.63 (1.32, 9.94)3.63 (1.32, 9.94) 8.588.58

Zaccarelli 1994 (Italy) 2.09 (1.14, 3.83)2.09 (1.14, 3.83) 12.5012.50

**Overall (I−squared = 73.4%, p = 0.000)** 1.99 (1.31, 3.04)1.99 (1.31, 3.04) 100.00100.00

NOTE: Weights are from random effects analysis

.5 1 2 4 6

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk.

Fig. 12. Ratios of crude mortality rates for AIDS-related death versus death from drug overdose in HIV-positive people who inject drugs

**%**

**Cohort** **RR (95% CI)** **Weight**

Eskild 1993 (Norway) 0.20 (0.07, 0.56)0.20 (0.07, 0.56) 6.846.84

Fingerhood 2006 (USA) 4.83 (2.02, 11.57)4.83 (2.02, 11.57) 7.347.34

Frischer 1997 (UK) 1.50 (0.26, 8.76)1.50 (0.26, 8.76) 4.604.60

Fugelstad 1995 (Sweden) 0.17 (0.08, 0.38)0.17 (0.08, 0.38) 7.577.57

Fugelstad 1997 (Sweden) 0.18 (0.10, 0.32)0.18 (0.10, 0.32) 8.258.25

Galli 1994 (Italy) 3.13 (2.06, 4.73)3.13 (2.06, 4.73) 8.628.62

Goedert 1995 (Italy) 5.08 (3.34, 7.72)5.08 (3.34, 7.72) 8.618.61

Golz 2001 (Germany) 2.00 (0.81, 4.93)2.00 (0.81, 4.93) 7.247.24

Manfredi 2006 (Italy) 1.81 (1.13, 2.88)1.81 (1.13, 2.88) 8.518.51

Solomon 2009 (India) 1.75 (0.74, 4.13)1.75 (0.74, 4.13) 7.397.39

van Haastrecht 1996 (Netherlands) 1.20 (0.52, 2.76)1.20 (0.52, 2.76) 7.477.47

Vlahov 2005 (USA) 1.70 (1.42, 2.04)1.70 (1.42, 2.04) 8.998.99

Zaccarelli 1994 (Italy) 3.56 (2.29, 5.53)3.56 (2.29, 5.53) 8.568.56

**Overall (I−squared = 92.5%, p = 0.000)** 1.35 (0.79, 2.31)1.35 (0.79, 2.31) 100.00100.00

NOTE: Weights are from random effects analysis

.0719 1 13.9

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk.

|Cohort|Col2|Col3|Weight RR (95% CI) %|Col5|Col6|
|---|---|---|---|---|---|
|Eskild 1993 (Norway) Frischer 1997 (UK) Fugelstad 1997 (Sweden) Galli 1994 (Italy) Goedert 1995 (Italy) Manfredi 2006 (Italy) Solomon 2009 (India) VanHaastrecht 1996 (Netherlands) Zaccarelli 1994 (Italy) Overall (I−squared = 73.4%, p = 0.000) NOTE: Weights are from random effects analysis|||22..0022 ((11..1188,, 33..4455)) 1133..2244 22..4411 ((00..5588,, 1100..0055)) 55..7744 33..5511 ((22..3333,, 55..2288)) 1144..5522 11..0044 ((00..7700,, 11..5566)) 1144..5577 33..9900 ((11..3366,, 1111..1188)) 88..2222 00..7777 ((00..4433,, 11..3388)) 1122..7755 22..1188 ((00..9922,, 55..1166)) 99..8888 33..6633 ((11..3322,, 99..9944)) 88..5588 22..0099 ((11..1144,, 33..8833)) 1122..5500 11..9999 ((11..3311,, 33..0044)) 110000..0000|||
|||||||
|||||||
|||||||

|Cohort|Col2|Col3|Weight RR (95% CI) %|Col5|
|---|---|---|---|---|
|Eskild 1993 (Norway) Fingerhood 2006 (USA) Frischer 1997 (UK) Fugelstad 1995 (Sweden) Fugelstad 1997 (Sweden) Galli 1994 (Italy) Goedert 1995 (Italy) Golz 2001 (Germany) Manfredi 2006 (Italy) Solomon 2009 (India) van Haastrecht 1996 (Netherlands) Vlahov 2005 (USA) Zaccarelli 1994 (Italy) Overall (I−squared = 92.5%, p = 0.000) NOTE: Weights are from random effects analysis|||00..2200 ((00..0077,, 00..5566)) 66..8844 44..8833 ((22..0022,, 1111..5577)) 77..3344 11..5500 ((00..2266,, 88..7766)) 44..6600 00..1177 ((00..0088,, 00..3388)) 77..5577 00..1188 ((00..1100,, 00..3322)) 88..2255 33..1133 ((22..0066,, 44..7733)) 88..6622 55..0088 ((33..3344,, 77..7722)) 88..6611 22..0000 ((00..8811,, 44..9933)) 77..2244 11..8811 ((11..1133,, 22..8888)) 88..5511 11..7755 ((00..7744,, 44..1133)) 77..3399 11..2200 ((00..5522,, 22..7766)) 77..4477 11..7700 ((11..4422,, 22..0044)) 88..9999 33..5566 ((22..2299,, 55..5533)) 88..5566 11..3355 ((00..7799,, 22..3311)) 110000..0000||
||||||
||||||
||||||
||||||
||||||


-----

o ta ty a o g peop e o ject d ugs y

Fig. 13. Ratios of crude mortality rates in HIV-positive males versus HIV-positive females who inject drugs

**Cohort** **RR (95% CI)**

Fugelstad 1998 (Sweden) 1.45 (0.65, 3.23)1.45 (0.65, 3.23)

Liu 2011 (China) 1.01 (0.81, 1.26)1.01 (0.81, 1.26)

Manfredi 2006 (Italy) 1.22 (0.89, 1.68)1.22 (0.89, 1.68)

Zaccarelli 1994 (Italy) 1.30 (0.89, 1.91)1.30 (0.89, 1.91)

**Overall (I−squared = 0.0%, p = 0.537)** 1.13 (0.96, 1.32)1.13 (0.96, 1.32)

NOTE: Weights are from random effects analysis

.5 1 3

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk.

Fig. 14. Ratios of crude mortality rates in HIV-negative males versus HIV-negative females who inject drugs

**Cohort** **RR (95% CI**

Fugelstad 1998 (Sweden) 2.14 (0.77, 5.93)2.14 (0.77, 5.93)

Manfredi 2006 (Italy) 1.46 (0.62, 3.44)1.46 (0.62, 3.44)

Zaccarelli 1994 (Italy) 2.02 (0.79, 5.15)2.02 (0.79, 5.15)

**Overall (I−squared = 0.0%, p = 0.820)** 1.81 (1.06, 3.09)1.81 (1.06, 3.09)

NOTE: Weights are from random effects analysis

.5 1 2 4

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk.


**%**

|Cohort|Col2|Col3|Weight RR (95% CI)|Col5|
|---|---|---|---|---|
|Fugelstad 1998 (Sweden) Liu 2011 (China) Manfredi 2006 (Italy) Zaccarelli 1994 (Italy) Overall (I−squared = 0.0%, p = 0.537) NOTE: Weights are from random effects analysis|||11..4455 ((00..6655,, 33..2233)) 33..9999 11..0011 ((00..8811,, 11..2266)) 5522..6622 11..2222 ((00..8899,, 11..6688)) 2255..8888 11..3300 ((00..8899,, 11..9911)) 1177..5500 11..1133 ((00..9966,, 11..3322)) 110000..0000||
||||||
||||||
||||||
||||||
||||||

|Cohort|Col2|Col3|Weight RR (95% CI %|Col5|Col6|
|---|---|---|---|---|---|
|Fugelstad 1998 (Sweden) Manfredi 2006 (Italy) Zaccarelli 1994 (Italy) Overall (I−squared = 0.0%, p = 0.820) NOTE: Weights are from random effects analysis|||22..1144 ((00..7777,, 55..9933)) 2277..6677 11..4466 ((00..6622,, 33..4444)) 3399..3311 22..0022 ((00..7799,, 55..1155)) 3333..0022 11..8811 ((11..0066,, 33..0099)) 110000..0000|||
|||||||
|||||||
|||||||
|||||||


The ability to detect differences in
mortality in cohort studies according to
HIV status is subject to limitations. HIV
status was typically measured at baseline
only, and some subjects who contracted
HIV infection during follow-up would
remain assigned to the HIV− group for
the entire follow-up period. Nonethe­
less, this would only serve to underesti­
mate the relative differences in mortality
between HIV+ and HIV− people who
inject drugs. The markedly higher all

in countries where drug injecting is
taking place but little research has been
conducted about it.

In this review we found no signifi­
cant differences in the risk of death by
type of primary drug injected. This con­
trasts with the findings of other reviews
of people dependent on different drug
types, which, despite their own limita­
tions, have suggested differences in
mortality among opioid-, amphetamineand cocaine-dependent persons.[3][–][5] An


explanation for this discrepancy might
lie in the extent of drug injection among
the groups examined, whether people
used multiple drugs (polydrug use be­
ing the norm), or the possibility, seldom
examined, that some people in the co­
horts switched from one primary drug
to another during the follow-up period.
All of these factors would have reduced
our capacity to detect any differences in
mortality among people injecting differ­
ent types of drugs.


-----

y y g p p j g


-----

o ta ty a o g peop e o ject d ugs y

Fig. 15. Ratios of crude mortality rates in people who inject drugs during in-treatment period versus off-treatment period

**Cohort** **RR (95% CI)**

Clausen 2008 (Norway) 1.96 (1.50, 2.56)1.96 (1.50, 2.56)

Cornish 2010 (UK) 1.90 (1.40, 2.59)1.90 (1.40, 2.59)

Davoli 2007 (Italy) 10.86 (7.25, 16.26)10.86 (7.25, 16.26)

Degenhardt 2009 (Australia) 1.92 (1.79, 2.05)1.92 (1.79, 2.05)

Fugelstad 1995 (Sweden) 1.19 (0.58, 2.45)1.19 (0.58, 2.45)

Fugelstad 1998 (Sweden) 2.55 (1.15, 5.66)2.55 (1.15, 5.66)

**Overall (I−squared = 93.0%, p = 0.000)** 2.52 (1.59, 4.00)2.52 (1.59, 4.00)

NOTE: Weights are from random effects analysis

1 5 10 15

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; RR, relative risk.

|Cohort|Col2|RR (95% CI) Weight %|Col4|Col5|Col6|
|---|---|---|---|---|---|
|Clausen 2008 (Norway) Cornish 2010 (UK) Davoli 2007 (Italy) Degenhardt 2009 (Australia) Fugelstad 1995 (Sweden) Fugelstad 1998 (Sweden) Overall (I−squared = 93.0%, p = 0.000) NOTE: Weights are from random effects analysis||11..9966 ((11..5500,, 22..5566)) 1188..6677 11..9900 ((11..4400,, 22..5599)) 1188..3322 1100..8866 ((77..2255,, 1166..2266)) 1177..3300 11..9922 ((11..7799,, 22..0055)) 1199..8855 11..1199 ((00..5588,, 22..4455)) 1133..3377 22..5555 ((11..1155,, 55..6666)) 1122..4499 22..5522 ((11..5599,, 44..0000)) 110000..0000||||
|||||||
|||||||


Table 3. **Univariate associations between study-level variables and all-cause crude**

**mortality rates (CMRs) and standardized mortality ratios (SMRs)**


ported in various forms, including odds
ratios, relative risks, hazard ratios and
CMRs. Most studies did not report
SMRs and many failed to report standard
parameters such as PY, or were seldom
easy to calculate, particularly for disag­
gregated mortality estimates. As a result,
only a subset of studies could be included
in many of the analyses.

Causes of death were not uniformly
or consistently coded. Deaths from
drug overdose might have been missed
in countries with limited capacity to
conduct toxicological tests or where
recording a death as being from a drug
overdose is surrounded by stigma. As
a result, we may have underestimated
CMRs and SMRs for death from drug
overdose. Misattribution of deaths by
HIV status may have occurred, since
most cohorts were assessed for HIV
status at the beginning of the study only
and people infected during follow-up
could have been missed. Again, this may
have resulted in conservative estimates
of mortality among HIV+ people who
inject drugs and in lower effect sizes. In
future research, assessing individuals’
HIV status at several time points during
the follow-up period would allow a more
accurate measurement of mortality in
relation to HIV status.


cause mortality that we observed among
HIV+ people who inject drugs is there­
fore probably a conservative estimate of
the elevation in mortality in that group.
Misattribution of cause of death as either
AIDS- or non-AIDS-related could have
occurred as well.

Treatment for HIV infection has
improved greatly and has become more
widely available. In some cohorts, mor­
tality was examined for the periods be­
fore and after highly active antiretroviral
therapy (HAART) was introduced. The
findings suggest that mortality among
HIV+ people who inject drugs decreased
after the widespread introduction of


HAART.[55] Unfortunately, we were un­
able to examine the impact of treatment
for HIV infection across studies because
mortality was rarely reported separately
for the periods before and after the in­
troduction of HAART.[77] However, the
observed association between cohorts
with more recent follow-up periods and
lower SMRs might have to do with the
greater availability in recent years of ef­
fective interventions for the prevention
and treatment of HIV infection.

Reporting quality was poor. Few
studies met criteria in consensus state­
ments for the reporting of observational
studies.[7] Mortality estimates were re­


-----

y y g p p j g

Fig. 16. Crude mortality rates for people who inject drugs, by country income group

**%**

**Cohort** **CMR (95% CI)** **Weight**

**high income**

Antolini 2006 (Italy) 2.01 (1.79, 2.16)2.01 (1.79, 2.16) 1.831.83

Bargagli 2001 (Italy) 2.15 (2.05, 2.25)2.15 (2.05, 2.25) 1.841.84

Bauer 2008 (Austria) 5.42 (3.45, 7.40)5.42 (3.45, 7.40) 0.770.77

Brancato 1995 (Italy) 2.04 (1.26, 2.83)2.04 (1.26, 2.83) 1.511.51

Ciccolallo 2000 (Italy) 2.26 (2.08, 2.43)2.26 (2.08, 2.43) 1.831.83

Clausen 2008 (Norway) 1.95 (1.70, 2.23)1.95 (1.70, 2.23) 1.801.80

Copeland 2004 (UK) 2.45 (2.06, 2.84)2.45 (2.06, 2.84) 1.751.75

Cornish 2010 (UK) 1.00 (0.86, 1.15)1.00 (0.86, 1.15) 1.831.83

Davoli 2007 (Italy) 0.74 (0.59, 0.88)0.74 (0.59, 0.88) 1.831.83

Degenhardt 2009 (Australia) 0.89 (0.86, 0.92)0.89 (0.86, 0.92) 1.851.85

Digusto 2004 (Australia) 1.27 (0.40, 2.29)1.27 (0.40, 2.29) 1.401.40

EMCDDA 2011 (Sweden) 3.33 (2.98, 3.68)3.33 (2.98, 3.68) 1.771.77

EMCDDA 2011 (Croatia) 1.09 (0.93, 1.25)1.09 (0.93, 1.25) 1.831.83

Eskild 1993 (Norway) 2.77 (2.22, 3.42)2.77 (2.22, 3.42) 1.641.64

Esteban 2003 (Spain) 3.68 (3.11, 4.25)3.68 (3.11, 4.25) 1.661.66

Evans 2012 (USA) 0.91 (0.62, 1.20)0.91 (0.62, 1.20) 1.791.79

Fingerhood 2006 (USA) 7.14 (5.22, 9.06)7.14 (5.22, 9.06) 0.800.80

Frischer 1997 (UK) 2.08 (1.52, 2.64)2.08 (1.52, 2.64) 1.661.66

Fugelstad 1995 (Sweden) 3.85 (2.94, 4.76)3.85 (2.94, 4.76) 1.431.43

Fugelstad 1997 (Sweden) 1.99 (1.72, 2.25)1.99 (1.72, 2.25) 1.801.80

Fugelstad 1998 (Sweden) 7.76 (5.54, 10.58)7.76 (5.54, 10.58) 0.570.57

Galli 1994 (Italy) 2.52 (2.28, 2.77)2.52 (2.28, 2.77) 1.811.81

Goedert 1995 (Italy) 1.57 (1.41, 1.75)1.57 (1.41, 1.75) 1.831.83

Goedert 2001 (USA) 4.67 (4.42, 4.92)4.67 (4.42, 4.92) 1.811.81

Golz 2001 (Germany) 4.22 (2.80, 5.64)4.22 (2.80, 5.64) 1.081.08

Haarr 2007 (Norway) 1.92 (0.95, 3.44)1.92 (0.95, 3.44) 1.191.19
Hickman 2003 (UK) 1.61 (1.13, 2.23)1.61 (1.13, 2.23) 1.671.67

Jarrin 2007 (Spain) 2.02 (1.92, 2.12)2.02 (1.92, 2.12) 1.841.84

Lejckova 2007 (Czech Republic) 0.84 (0.75, 0.93)0.84 (0.75, 0.93) 1.841.84

Lumbreras 2006 (Spain) 2.18 (2.00, 2.36)2.18 (2.00, 2.36) 1.831.83

Manfredi 2006 (Italy) 2.04 (1.80, 2.30)2.04 (1.80, 2.30) 1.811.81
McAnulty 1995 (USA) 1.05 (0.69, 1.41)1.05 (0.69, 1.41) 1.771.77

Mezzelani 1998 (Italy) 2.91 (2.48, 3.33)2.91 (2.48, 3.33) 1.741.74

Miller 2007 (Canada) 1.37 (0.80, 1.94)1.37 (0.80, 1.94) 1.651.65

Moroni 1991 (Italy) 2.43 (2.16, 2.69)2.43 (2.16, 2.69) 1.801.80

Muga 2007 (Spain) 3.74 (3.38, 4.14)3.74 (3.38, 4.14) 1.761.76

Nyhlen 2011 (Sweden) 1.30 (1.12, 1.48)1.30 (1.12, 1.48) 1.831.83

O’Driscoll 2001 (USA) 1.59 (1.22, 1.96)1.59 (1.22, 1.96) 1.761.76

Oppenheimer 1994 (UK) 1.83 (1.28, 2.38)1.83 (1.28, 2.38) 1.671.67

Reece 2010 (Australia) 0.50 (0.36, 0.65)0.50 (0.36, 0.65) 1.831.83

Sanchez−Carbonell 2000 (Spain) 3.40 (2.36, 4.44)3.40 (2.36, 4.44) 1.331.33

Seaman 1998 (UK) 2.33 (1.60, 3.27)2.33 (1.60, 3.27) 1.481.48

Sorensen 2005 (Denmark) 3.49 (2.45, 4.53)3.49 (2.45, 4.53) 1.331.33

Stenbacka 2007 (Sweden) 2.12 (1.93, 2.31)2.12 (1.93, 2.31) 1.821.82

Stoove 2008 (Australia) 0.83 (0.56, 1.21)0.83 (0.56, 1.21) 1.781.78

Tait 2008 (Australia) 0.50 (0.29, 0.72)0.50 (0.29, 0.72) 1.821.82

VanHaastrecht 1996 (Netherlands) 3.23 (2.56, 4.07)3.23 (2.56, 4.07) 1.541.54

Vlahov 2005 (USA) 4.50 (4.24, 4.76)4.50 (4.24, 4.76) 1.801.80

Vlahov 2008 (USA) 0.71 (0.54, 0.88)0.71 (0.54, 0.88) 1.831.83

Zabransky 2011 (Czech Republic) 0.48 (0.15, 0.81)0.48 (0.15, 0.81) 1.781.78

Zaccarelli 1994 (Italy) 2.30 (1.96, 2.63)2.30 (1.96, 2.63) 1.781.78

Subtotal (I−squared = 98.8%, p = 0.000) 2.17 (1.92, 2.42)2.17 (1.92, 2.42) 83.9983.99

.

**low and middle income**

Azim 2008 (Bangladesh) 6.32 (4.68, 7.96)6.32 (4.68, 7.96) 0.940.94

Azim 2009 (Bangladesh) 3.52 (2.46, 4.59)3.52 (2.46, 4.59) 1.311.31

Cardoso 2006 (Brazil) 2.77 (1.45, 4.09)2.77 (1.45, 4.09) 1.141.14

EMCDDA 2011 (Romania) 0.57 (0.47, 0.68)0.57 (0.47, 0.68) 1.841.84

EMCDDA 2011 (Bulgaria) 1.18 (0.91, 1.46)1.18 (0.91, 1.46) 1.801.80

EMCDDA 2011 (Latvia) 1.60 (1.43, 1.77)1.60 (1.43, 1.77) 1.831.83

Jafan 2010 (Islamic Republic of Iran) 4.08 (1.25, 6.91)4.08 (1.25, 6.91) 0.480.48

Liu 2011 (China) 6.89 (5.79, 7.98)6.89 (5.79, 7.98) 1.291.29

Moskalewicz 1996 (Poland) 2.28 (1.81, 2.83)2.28 (1.81, 2.83) 1.691.69

Quan 2007 (Thailand) 3.85 (2.42, 5.83)3.85 (2.42, 5.83) 0.910.91

Quan 2010 (Viet Nam) 6.30 (4.60, 8.50)6.30 (4.60, 8.50) 0.780.78

Rahimi-Movahgar 2009 (Islamic Republic of Iran) 4.83 (0.00, 14.30)4.83 (0.00, 14.30) 0.100.10

Solomon 2009 (India) 4.25 (3.35, 5.16)4.25 (3.35, 5.16) 1.431.43

Zhang 2005 (China) 7.73 (4.87, 10.60)7.73 (4.87, 10.60) 0.470.47

Subtotal (I−squared = 97.0%, p = 0.000) 3.53 (2.81, 4.24)3.53 (2.81, 4.24) 16.0116.01

.
**Overall (I−squared = 98.6%, p = 0.000)** 2.35 (2.12, 2.58)2.35 (2.12, 2.58) 100.00100.00

NOTE: Weights are from random effects analysis

−10 −5 0 5 10 15

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America).
CI, confidence interval; CMR, crude mortality rate.

|Cohort|Col2|Col3|CMR (95% CI) Weight %|Col5|Col6|
|---|---|---|---|---|---|
|high income Antolini 2006 (Italy) Bargagli 2001 (Italy) Bauer 2008 (Austria) Brancato 1995 (Italy) Ciccolallo 2000 (Italy) Clausen 2008 (Norway) Copeland 2004 (UK) Cornish 2010 (UK) Davoli 2007 (Italy) Degenhardt 2009 (Australia) Digusto 2004 (Australia) EMCDDA 2011 (Sweden) EMCDDA 2011 (Croatia) Eskild 1993 (Norway) Esteban 2003 (Spain) Evans 2012 (USA) Fingerhood 2006 (USA) Frischer 1997 (UK) Fugelstad 1995 (Sweden) Fugelstad 1997 (Sweden) Fugelstad 1998 (Sweden) Galli 1994 (Italy) Goedert 1995 (Italy) Goedert 2001 (USA) Golz 2001 (Germany) Haarr 2007 (Norway) Hickman 2003 (UK) Jarrin 2007 (Spain) Lejckova 2007 (Czech Republic) Lumbreras 2006 (Spain) Manfredi 2006 (Italy) McAnulty 1995 (USA) Mezzelani 1998 (Italy) Miller 2007 (Canada) Moroni 1991 (Italy) Muga 2007 (Spain) Nyhlen 2011 (Sweden) O’Driscoll 2001 (USA) Oppenheimer 1994 (UK) Reece 2010 (Australia) Sanchez−Carbonell 2000 (Spain) Seaman 1998 (UK) Sorensen 2005 (Denmark) Stenbacka 2007 (Sweden) Stoove 2008 (Australia) Tait 2008 (Australia) VanHaastrecht 1996 (Netherlands) Vlahov 2005 (USA) Vlahov 2008 (USA) Zabransky 2011 (Czech Republic) Zaccarelli 1994 (Italy) Subtotal (I−squared = 98.8%, p = 0.000) . low and middle income Azim 2008 (Bangladesh) Azim 2009 (Bangladesh) Cardoso 2006 (Brazil) EMCDDA 2011 (Romania) EMCDDA 2011 (Bulgaria) EMCDDA 2011 (Latvia) Jafan 2010 (Islamic Republic of Iran) Liu 2011 (China) Moskalewicz 1996 (Poland) Quan 2007 (Thailand) Quan 2010 (Viet Nam) Rahimi-Movahgar 2009 (Islamic Republic of Iran) Solomon 2009 (India) Zhang 2005 (China) Subtotal (I−squared = 97.0%, p = 0.000) . Overall (I−squared = 98.6%, p = 0.000) NOTE: Weights are from random effects analysis|||22..0011 ((11..7799,, 22..1166)) 11..8833 22..1155 ((22..0055,, 22..2255)) 11..8844 55..4422 ((33..4455,, 77..4400)) 00..7777 22..0044 ((11..2266,, 22..8833)) 11..5511 22..2266 ((22..0088,, 22..4433)) 11..8833 11..9955 ((11..7700,, 22..2233)) 11..8800 22..4455 ((22..0066,, 22..8844)) 11..7755 11..0000 ((00..8866,, 11..1155)) 11..8833 00..7744 ((00..5599,, 00..8888)) 11..8833 00..8899 ((00..8866,, 00..9922)) 11..8855 11..2277 ((00..4400,, 22..2299)) 11..4400 33..3333 ((22..9988,, 33..6688)) 11..7777 11..0099 ((00..9933,, 11..2255)) 11..8833 22..7777 ((22..2222,, 33..4422)) 11..6644 33..6688 ((33..1111,, 44..2255)) 11..6666 00..9911 ((00..6622,, 11..2200)) 11..7799 77..1144 ((55..2222,, 99..0066)) 00..8800 22..0088 ((11..5522,, 22..6644)) 11..6666 33..8855 ((22..9944,, 44..7766)) 11..4433 11..9999 ((11..7722,, 22..2255)) 11..8800 77..7766 ((55..5544,, 1100..5588)) 00..5577 22..5522 ((22..2288,, 22..7777)) 11..8811 11..5577 ((11..4411,, 11..7755)) 11..8833 44..6677 ((44..4422,, 44..9922)) 11..8811 44..2222 ((22..8800,, 55..6644)) 11..0088 11..9922 ((00..9955,, 33..4444)) 11..1199 11..6611 ((11..1133,, 22..2233)) 11..6677 22..0022 ((11..9922,, 22..1122)) 11..8844 00..8844 ((00..7755,, 00..9933)) 11..8844 22..1188 ((22..0000,, 22..3366)) 11..8833 22..0044 ((11..8800,, 22..3300)) 11..8811 11..0055 ((00..6699,, 11..4411)) 11..7777 22..9911 ((22..4488,, 33..3333)) 11..7744 11..3377 ((00..8800,, 11..9944)) 11..6655 22..4433 ((22..1166,, 22..6699)) 11..8800 33..7744 ((33..3388,, 44..1144)) 11..7766 11..3300 ((11..1122,, 11..4488)) 11..8833 11..5599 ((11..2222,, 11..9966)) 11..7766 11..8833 ((11..2288,, 22..3388)) 11..6677 00..5500 ((00..3366,, 00..6655)) 11..8833 33..4400 ((22..3366,, 44..4444)) 11..3333 22..3333 ((11..6600,, 33..2277)) 11..4488 33..4499 ((22..4455,, 44..5533)) 11..3333 22..1122 ((11..9933,, 22..3311)) 11..8822 00..8833 ((00..5566,, 11..2211)) 11..7788 00..5500 ((00..2299,, 00..7722)) 11..8822 33..2233 ((22..5566,, 44..0077)) 11..5544 44..5500 ((44..2244,, 44..7766)) 11..8800 00..7711 ((00..5544,, 00..8888)) 11..8833 00..4488 ((00..1155,, 00..8811)) 11..7788 22..3300 ((11..9966,, 22..6633)) 11..7788 22..1177 ((11..9922,, 22..4422)) 8833..9999 66..3322 ((44..6688,, 77..9966)) 00..9944 33..5522 ((22..4466,, 44..5599)) 11..3311 22..7777 ((11..4455,, 44..0099)) 11..1144 00..5577 ((00..4477,, 00..6688)) 11..8844 11..1188 ((00..9911,, 11..4466)) 11..8800 11..6600 ((11..4433,, 11..7777)) 11..8833 44..0088 ((11..2255,, 66..9911)) 00..4488 66..8899 ((55..7799,, 77..9988)) 11..2299 22..2288 ((11..8811,, 22..8833)) 11..6699 33..8855 ((22..4422,, 55..8833)) 00..9911 66..3300 ((44..6600,, 88..5500)) 00..7788 44..8833 ((00..0000,, 1144..3300)) 00..1100 44..2255 ((33..3355,, 55..1166)) 11..4433 77..7733 ((44..8877,, 1100..6600)) 00..4477 33..5533 ((22..8811,, 44..2244)) 1166..0011 22..3355 ((22..1122,, 22..5588)) 110000..0000|||
|||||||


-----

o ta ty a o g peop e o ject d ugs y


AIDS-related mortality in settings with a
high prevalence of HIV infection. HIV+
people who inject drugs have higher
mortality not just from HIV-related
causes but also from drug overdose.
Mortality varies by participant- and
study-level characteristics, which sug­
gests that multiple factors contribute
to the higher risk of death observed in
people who inject drugs. Many of these
factors are probably modifiable, since
certain predominant causes of death ac­
count for most of the mortality observed
in this group. ■

**Competing interests: None declared.**


###### Limitations of the review and meta-analysis

Our review has limitations. The lag
time between the date when the studies
were conducted and when they were
published in peer-reviewed journals was
generally long. In light of this we used
several methods to search for published
and unpublished studies. We reviewed
primarily English-language papers,
although we also reviewed the abstracts
of non-English-language peer-reviewed
articles when they were available in
English. When studies seemed relevant,
we had them translated; we engaged ex­
perts from a range of different countries
and language groups to review these


reference lists. Meta-analytical methods
were originally developed to aggregate
the findings of randomized controlled
trials,[85] which have the advantage of
allowing for control or adjustment of
pre-conditions and sample-related fac­
tors that could influence the outcomes
of interest. Controlling for such factors
is not possible in observational studies,
like the ones included in our review.

##### Conclusion

People who inject drugs have a much
higher risk of death than those who do
not. Major causes of death in this group
are often poorly specified, but death
from drug overdose is common, as is


### ملخص
#### معدل الوفيات بني األشخاص الذين يتعاطون املخدرات عن طريق احلقن: استعراض منهجي وحتليل وصفي

###### 14.68 الثنتني وثالثني جمموعة؛ وكانت نسبة الوفيات املوحدة استعراض الدراسات األترابية املعنية بمعدل الوفيات بني الغرض ). وأظهرت مقارنة 16.35  إىل13.01 :% 95 (فاصل الثقة األشخاص الذين يتعاطون املخدرات عن طريق احلقن عىل نحو معدالت الوفيات األولية وحساب نسب معدالت الوفيات منهجي، ودراسة معدالت الوفيات وأسباب الوفاة يف هذه الفئة، األولية ارتفاع معدل الوفيات يف البلدان املنخفضة واملتوسطة وحتديد متغريات مستوى املشاركني والدراسة املرتبطة بارتفاع الدخل بني املجموعات والذكور واألشخاص اإلجيابيني لفريوس خطر الوفاة. ) الذين تعاطوا املخدرات عن طريق HIV( العوز املناعي البرشي  تم استخدام عبارات بحث خمصصة للبحث يف قواعد الطريقة كذلك خالل فرتات وقف العالج. احلقن. وكان املعدل مرتفعا[ً] . وتم حتديد PsycINFO وMedline وEMBASE بيانات وكان فرط جرعة املخدرات ومتالزمة العوز املناعي املكتسب الكتابات غري الرسمية من خالل قواعد بيانات الكتابات غري
 (األيدز) السببني الرئيسيني للوفاة بني املجموعات. الرسمية عىل شبكة اإلنرتنت. وتم استشارة اخلرباء للحصول  مقارنة بعامة السكان، يتعرض األشخاص الذين االستنتاج عىل دراسات وبيانات إضافية. وتم إجراء التحليالت الوصفية يتعاطون املخدرات عن طريق احلقن خلطر وفاة مرتفع، عىل الرغم للتأثريات العشوائية لتقييم معدالت الوفيات األولية املجمعة من تفاوت معدالت الوفيات بني البيئات املختلفة. وجيب أن ).SMRs( ) ونسب الوفيات املوحدةCMRs( يتضمن أي هنج شامل لتحسني حصائل الصحة يف هذه الفئة جهودا[ً]  تم حتديد سبع وستني جمموعة من األشخاص الذينالنتائج خلفض عدوى اإلصابة بفريوس العوز املناعي البرشي باإلضافة يتعاطون املخدرات عن طريق احلقن، أربع عرشة منها من البلدان
 إىل غريها من أسباب الوفاة، والسيام فرط جرعة املخدرات. املنخفضة واملتوسطة الدخل. وكان معدل الوفيات األويل املجمع
 ، فاصل % 95 سنة (فاصل الثقة- شخص100 وفاة لكل2.35 ). وتم اإلبالغ عن نسب الوفيات املوحدة2.58 إىل2.12 :الثقة

 摘要

 药物注射人群的死亡率：系统回顾和荟萃分析
目的 系统回顾药物注射人群死亡率的队列研究，检查该群 集的SMR为14.68（95% CI：13.01-16.35）。CMR的比
体的死亡率和死亡原因，并确定与较高死亡风险相关的参 较和CMR比率的计算表明，中低收入国家的队列、男性
与水平和研究水平变量。 以及艾滋病毒（HIV）呈阳性的药物注射人群中的死亡率
方法 使用定制的搜索字符串搜索EMBASE、Medline和 较高。治疗结束期间死亡率也较高。药物过量和艾滋病
PsycINFO。通过网上灰色文献数据库识别灰色文献。咨询 （AIDS）是各个队列的主要死亡原因。
专家以获取更多的研究和数据。执行随机效果荟萃分析来 结论 尽管不同环境中的死亡率各异，与普通人群相比，药
估计汇集的粗死亡率（CMR）和标准化死亡率（SMR）。 物注射人群的死亡风险更高。任何改善该群体的健康疗效
结果 确定67 个药物注射人群队列，其中14 个来自中低 的综合方案都必须包括减少艾滋病毒感染以及其他死亡致
收入国家。汇集的CMR为每100 人年2.35 例死亡（95% 因（尤其是药物过量）的努力。
置信区间，CI：2.12-2.58）。报告32 个队列的SMR；汇


-----

y y g p p j g

###### Résumé

 Mortalité chez les personnes qui s’injectent des drogues : revue systématique et méta-analyse
**Objectif Examiner systématiquement les études de cohortes de la** Les TMS étaient indiqués pour 32 cohortes, avec un TMS groupé de 14,68
mortalité chez les toxicomanes par injection, étudier les taux de mortalité (IC de 95%: 13,01 – 16,35). La comparaison des TBM et le calcul des taux
et les causes de décès dans ce groupe, et identifier les variables, au niveau de TMS ont révélé une mortalité plus élevée parmi les cohortes des pays
des participants et des études, associées à un risque accru de décès. à revenu faible et intermédiaire, les sujets masculins et les toxicomanes
**Méthodes Des critères de recherche spécifiquement adaptés ont été** par injection séropositifs. Elle était également plus élevée pendant
utilisés pour les recherches réalisées sur EMBASE, Medline et PsycINFO. les périodes d’interruption thérapeutique. L’overdose et le syndrome
La littérature grise a été identifiée par le biais de bases de données de d’immunodéficience acquise (SIDA) étaient les causes principales des
littérature grise disponibles en ligne. Des experts ont été consultés pour décès parmi ces cohortes.
obtenir des données et des études supplémentaires. Des méta-analyses **Conclusion Si l’on compare avec la population globale, les personnes**
des effets aléatoires ont été réalisées afin d’estimer les taux bruts de qui s’injectent des drogues ont un risque élevé de décès, bien que les
mortalité (TBM) groupés et les taux de mortalité standardisés (TMS). taux de mortalité varient selon les contextes. Toute approche exhaustive
**Résultats Soixante-sept cohortes de personnes qui s’injectent des** visant à améliorer les résultats de ce groupe en matière de santé doit
drogues ont été identifiées, dont 14 appartenant à des pays à revenu comprendre des efforts en vue de diminuer l’infection par le VIH, ainsi
faible et intermédiaire. Le TBM groupé était de 2,35 décès pour que d’autres causes de décès, notamment l’overdose.
100 personnes-années (intervalle de confiance de 95%, IC: 2,12 – 2,58).

###### Резюме

 Смертность среди лиц, вводящих наркотики внутривенно: систематический обзор и мета-анализ
**Цель Провести систематический обзор когортных исследований** интервал, ДИ: 2,12–2,58). СКС фиксировался для 32 когорт;
смертности среди лиц, вводящих наркотики внутривенно, суммарный СКС составлял 14,68 (95% ДИ: 13,01-16,35). Сравнение
изучить уровни смертности и причины смерти в данной группе и ОПС и расчет коэффициентов ОПС выявил высокий уровень
определить переменные на уровне участников и исследований, смертности в когортах, относящихся к странам с низким и
связанные с высоким риском смерти. средним уровнями доходов, среди мужчин и лиц, вводивших
**Методы Поиск исследований осуществлялся по базам данных** наркотики внутривенно, которые имели положительные
EMBASE, Medline и PsycINFO по специализированным критериям результаты на вирус иммунодефицита человека (ВИЧ). Высокий
поиска. Поиск литературы для служебного пользования уровень также отмечен вне периодов лечения. Передозировка
осуществлялся по онлайновым базам данных литературы для наркотиков и синдром приобретенного иммунодефицита (СПИД)
служебного пользования. С целью получения дополнительных являлись основными причинами смерти в когортах.
данных и исследований проводились консультации с экспертами. **Вывод По сравнению с населением в целом, лица, вводящие**
Для определения суммарных общих показателей смертности наркотики внутривенно, подвержены повышенному риску
(ОПС) и стандартизированных коэффициентов смертности (СКС) смерти несмотря на то, что уровни смертности варьируются
выполнялся мета-анализ случайных эффектов. в зависимости от условий. Любой комплексный подход к
**Результаты Были выявлены шестьдесят семь когорт лиц,** улучшению результатов мероприятий по охране здоровья в
вводящих наркотики внутривенно, 14 из которых относятся к данной группе должен включать в себя меры по сокращению
странам с низким и средним уровнями доходов. Суммарный ОПС уровня ВИЧ-инфекции, а также других причин смерти, в
составлял 2,35 смертей на 100 человеко-лет (95% доверительный особенности, передозировки наркотиков.

###### Resumen

 La mortalidad entre consumidores de drogas inyectables: una revisión sistemática y meta-análisis
**Objetivo Revisar de forma sistemática los estudios de cohortes sobre la** para 32 cohortes; la tasa bruta combinada de mortalidad fue de 14,68
mortalidad entre los consumidores de drogas inyectables, examinar las (IC 95%: 13,01-16,35). La comparación de las tasas brutas combinadas
tasas de mortalidad y las causas de muerte en este grupo e identificar de mortalidad y el cálculo de las proporciones de la mortalidad
las variables relacionadas con el estudio y los participantes asociadas a bruta combinada revelaron que la mortalidad fue superior en las
un mayor riesgo de muerte. cohortes de países con ingresos bajos y medios, en varones y entre
**Métodos Se emplearon cadenas de búsqueda adaptadas para registrar** consumidores de drogas inyectables que dieron positivo para el virus
EMBASE, Medline y PsycINFO. La literatura gris se identificó por medio de de la inmunodeficiencia humana (VIH), así como durante los periodos
bases de datos de literatura gris en línea. Se consultaron expertos a fin sin tratamiento. Las sobredosis y el síndrome de la inmunodeficiencia
de obtener datos y estudios adicionales y se llevaron a cabo metaanálisis adquirida (SIDA) fueron las causas principales de muerte en las cohortes.
de efectos aleatorios para calcular las tasas brutas combinadas de **Conclusión En comparación con la población general, los consumidores**
mortalidad y las tasas de mortalidad estandarizadas. de drogas inyectables presentan un riesgo elevado de muerte, si bien
**Resultados Se identificaron diecisiete cohortes de consumidores** las tasas de mortalidad varían en los distintos lugares. Cualquier enfoque
de drogas inyectables, 14 de las cuales en países con ingresos completo para mejorar los resultados sanitarios en este grupo deberá
bajos y medios. La tasa bruta combinada de mortalidad fue de 2,35 esforzarse por reducir la infección por VIH, así como las otras causas de
fallecimientos por cada 100 años-persona (intervalo de confianza del muerte, en especial, la sobredosis.
95%, IC: 2,12-2,58). Se declararon las tasas de mortalidad estandarizadas


-----

o ta ty a o g peop e o ject d ugs y

###### References


1. Darke S, Degenhardt L, Mattick RP, editors. Mortality amongst illicit drug users.
Cambridge: Cambridge University Press; 2006.
2. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate
mortality among injecting drug users that is not attributable to AIDS. Sex
_[Transm Infect 2006;82:iii56–63. doi:10.1136/sti.2005.019273 PMID:16735295](http://dx.doi.org/10.1136/sti.2005.019273)_
3. Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S et al. Mortality
among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend
[2011;113:88–95. doi:10.1016/j.drugalcdep.2010.07.026 PMID:20828942](http://dx.doi.org/10.1016/j.drugalcdep.2010.07.026)
4. Singleton J, Degenhardt L, Hall W, Zabransky T. Mortality among amphetamine
users: a systematic review of cohort studies. Drug Alcohol Depend 2009;105:1–8.
[doi:10.1016/j.drugalcdep.2009.05.028 PMID:19631479](http://dx.doi.org/10.1016/j.drugalcdep.2009.05.028)
5. Degenhardt L, McLaren J, Ali H, Briegleb C; Global Burden of Disease Mental
Disorders and Illicit Drug Use Expert Group. Methods used in a systematic
_review of mortality among dependent users of heroin and other opioids. Sydney:_
National Drug and Alcohol Research Centre, University of New South Wales;
2008 (Illicit drugs discussion paper No. 9).
6. Calabria B, Phillips B, Singleton J, Mathers BM, Congreve E, Degenhardt L, et al.
_Searching the grey literature to access information on drug and alcohol research: A_
_resource to identify drug related databases and websites. Sydney: National Drug_
and Alcohol Research Centre, University of New South Wales; 2008.
7. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock
SJ et al. STROBE Initiative. Strengthening the reporting of observational
studies in epidemiology (STROBE): explanation and elaboration. Epidemiology
[2007;18:805–35. doi:10.1097/EDE.0b013e3181577511 PMID:18049195](http://dx.doi.org/10.1097/EDE.0b013e3181577511)
8. Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders
and completed suicide: an empirical review of cohort studies. Drug Alcohol
_[Depend 2004;76(Suppl):S11–9. doi:10.1016/j.drugalcdep.2004.08.003](http://dx.doi.org/10.1016/j.drugalcdep.2004.08.003)_
[PMID:15555812](http://www.ncbi.nlm.nih.gov/pubmed/15555812)
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials
[1986;7:177–88. doi:10.1016/0197-2456(86)90046-2 PMID:3802833](http://dx.doi.org/10.1016/0197-2456(86)90046-2)
10. Sharp S, Sterne J. Meta-analysis. Stata Tech Bull 1997;38:9–14.
11. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency

[in meta-analyses. BMJ 2003;327:557–60. doi:10.1136/bmj.327.7414.557](http://dx.doi.org/10.1136/bmj.327.7414.557)
[PMID:12958120](http://www.ncbi.nlm.nih.gov/pubmed/12958120)
12. Sharp S, Sterne J. Meta-analysis regression. Stata Tech Bull 1998;42:16–24.
13. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a

[comparison of methods. Stat Med 1999;18:2693–708. doi:10.1002/(SICI)1097-](http://dx.doi.org/10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V)
[0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V PMID:10521860](http://dx.doi.org/10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V)
14. Antolini G, Pirani M, Morandi G, Sorio C. Differenze di genere e mortalità in una

coorte di eroinomani nelle province emiliane di Modena e Ferrara [Gender
difference and mortality in a cohort of heroin users in the Provinces of Modena
[and Ferrara, 1975–1999]. Epidemiol Prev 2006;30:91–9. PMID:16909957](http://www.ncbi.nlm.nih.gov/pubmed/16909957)
15. Azim T, Chowdhury EI, Reza M, Faruque MO, Ahmed G, Khan R et al.

Prevalence of infections, HIV risk behaviors and factors associated with HIV
infection among male injecting drug users attending a needle/syringe
exchange program in Dhaka, Bangladesh. Subst Use Misuse 2008;43:2124–44.
[doi:10.1080/10826080802344583 PMID:19085439](http://dx.doi.org/10.1080/10826080802344583)
16. Azim T, Khan SI, Nahar Q, Reza M, Alam N, Saifi R, et al. 20 years of HIV in

_Bangladesh: experiences and way forward. Washington: World Bank; 2009._
17. Bargagli AM, Sperati A, Davoli M, Forastiere F, Perucci CA. Mortality among

problem drug users in Rome: an 18-year follow-up study, 1980–97. Addiction
[2001;96:1455–63. doi:10.1046/j.1360-0443.2001.961014559.x PMID:11571064](http://dx.doi.org/10.1046/j.1360-0443.2001.961014559.x)
18. Bauer SM, Loipl R, Jagsch R, Gruber D, Risser D, Thau K et al. Mortality in

opioid-maintained patients after release from an addiction clinic. Eur Addict Res
[2008;14:82–91. doi:10.1159/000113722 PMID:18334818](http://dx.doi.org/10.1159/000113722)
19. Brancato V, Delvecchio G, Simone P. Sopravvivenza e mortalità in una coorte

di tossicodipendenti da eroina nel periodo 1985–1994 [Survival and mortality
in a cohort of heroin addicts in 1985–1994]. Minerva Med 1995;86:97–9.
[PMID:7603612](http://www.ncbi.nlm.nih.gov/pubmed/7603612)
20. Cardoso MN, Caiaffa WT, Mingoti SA. Projeto AjUDE-Brasil II. AIDS incidence

and mortality in injecting drug users: the AjUDE-Brasil II Project. Cad
_[Saude Publica 2006;22:827–37. doi:10.1590/S0102-311X2006000400021](http://dx.doi.org/10.1590/S0102-311X2006000400021)_
[PMID:16612436](http://www.ncbi.nlm.nih.gov/pubmed/16612436)
21. Ciccolallo L, Morandi G, Pavarin R, Sorio C, Buiatti E. La mortalità dei

tossicodipendenti nella Regione Emilia Romagna e i suoi determinanti.
Risultati di uno studio longitudinale [Mortality risk in intravenous drug users in
Emilia Romagna region and its socio-demographic determinants. Results of a
[longitudinal study]. Epidemiol Prev 2000;24:75–80. PMID:10863848](http://www.ncbi.nlm.nih.gov/pubmed/10863848)
22. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid

maintenance treatment (OMT): a national prospective cross-registry study.
_[Drug Alcohol Depend 2008;94:151–7. doi:10.1016/j.drugalcdep.2007.11.003](http://dx.doi.org/10.1016/j.drugalcdep.2007.11.003)_
[PMID:18155364](http://www.ncbi.nlm.nih.gov/pubmed/18155364)


23. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death

during and after opiate substitution treatment in primary care: prospective
observational study in UK General Practice Research Database. BMJ
[2010;341:c5475. doi:10.1136/bmj.c5475 PMID:20978062](http://dx.doi.org/10.1136/bmj.c5475)
24. Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes

of death in a cohort of injecting drug users, 1980–2001. Arch Intern Med
[2004;164:1214–20. doi:10.1001/archinte.164.11.1214 PMID:15197047](http://dx.doi.org/10.1001/archinte.164.11.1214)
25. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M et al.

VEdeTTE Study Group. Risk of fatal overdose during and after specialist
drug treatment: the VEdeTTE study, a national multi-site prospective cohort
[study. Addiction 2007;102:1954–9. doi:10.1111/j.1360-0443.2007.02025.x](http://dx.doi.org/10.1111/j.1360-0443.2007.02025.x)
[PMID:18031430](http://www.ncbi.nlm.nih.gov/pubmed/18031430)
26. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among

clients of a state-wide opioid pharmacotherapy program over 20 years: risk
[factors and lives saved. Drug Alcohol Depend 2009;105:9–15. doi:10.1016/j.](http://dx.doi.org/10.1016/j.drugalcdep.2009.05.021)
[drugalcdep.2009.05.021 PMID:19608355](http://dx.doi.org/10.1016/j.drugalcdep.2009.05.021)
27. DiGiusto E, Shakeshaft A, Ritter A, O’Brien S, Mattick RP; NEPOD Research

Group. Serious adverse events in the Australian National Evaluation of
Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004;99:450–
[60. doi:10.1111/j.1360-0443.2004.00654.x PMID:15049745](http://dx.doi.org/10.1111/j.1360-0443.2004.00654.x)
28. Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P. Differences in

mortality rates and causes of death between HIV positive and HIV negative
[intravenous drug users. Int J Epidemiol 1993;22:315–20. doi:10.1093/](http://dx.doi.org/10.1093/ije/22.2.315)
[ije/22.2.315 PMID:8505190](http://dx.doi.org/10.1093/ije/22.2.315)
29. Esteban J, Gimeno C, Barril J, Aragonés A, Climent JM, de la Cruz Pellín M.

Survival study of opioid addicts in relation to its adherence to methadone
[maintenance treatment. Drug Alcohol Depend 2003;70:193–200. doi:10.1016/](http://dx.doi.org/10.1016/S0376-8716(03)00002-4)
[S0376-8716(03)00002-4 PMID:12732413](http://dx.doi.org/10.1016/S0376-8716(03)00002-4)
30. European Monitoring Centre on Drugs and Drug Addiction. Mortality related to

_drug use in Europe: public health implications. Lisbon: EMCDDA; 2011._
31. Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young

injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J
_[Epidemiol 2012;175:302–8. doi:10.1093/aje/kwr318 PMID:22227793](http://dx.doi.org/10.1093/aje/kwr318)_
32. Ferri M, Bargagli AM, Faggiano F, Belleudi V, Salamina G, Vigna-Taglianti F

et al. Gruppo di studio VEdeTTE. Mortalità in una coorte di tossicodipendenti
da eroina arruolati presso i Ser.T in Italia, 1998–2001 [Mortality of drug users
attending public treatment centers in Italy 1998–2001: a cohort study].
_[Epidemiol Prev 2007;31:276–82. PMID:18274231](http://www.ncbi.nlm.nih.gov/pubmed/18274231)_
33. Fingerhood M, Rastegar DA, Jasinski D. Five year outcomes of a cohort of

HIV-infected injection drug users in a primary care practice. J Addict Dis
[2006;25:33–8. doi:10.1300/J069v25n02_05 PMID:16785217](http://dx.doi.org/10.1300/J069v25n02_05)
34. Frischer M, Goldberg D, Rahman M, Berney L. Mortality and survival among a

cohort of drug injectors in Glasgow, 1982–1994. Addiction 1997;92:419–27.
[doi:10.1111/j.1360-0443.1997.tb03373.x PMID:9177063](http://dx.doi.org/10.1111/j.1360-0443.1997.tb03373.x)
35. Fugelstad A, Rajs J, Böttiger M, Gerhardsson de Verdier M. Mortality among

HIV-infected intravenous drug addicts in Stockholm in relation to methadone
[treatment. Addiction 1995;90:711–6. doi:10.1111/j.1360-0443.1995.tb02209.x](http://dx.doi.org/10.1111/j.1360-0443.1995.tb02209.x)
[PMID:7795507](http://www.ncbi.nlm.nih.gov/pubmed/7795507)
36. Fugelstad A, Annell A, Rajs J, Agren G. Mortality and causes and manner of

death among drug addicts in Stockholm during the period 1981–1992. Acta
_[Psychiatr Scand 1997;96:169–75. doi:10.1111/j.1600-0447.1997.tb10147.x](http://dx.doi.org/10.1111/j.1600-0447.1997.tb10147.x)_
[PMID:9296546](http://www.ncbi.nlm.nih.gov/pubmed/9296546)
37. Fugelstad A, Agren G, Romelsjö A. Changes in mortality, arrests,

and hospitalizations in nonvoluntarily treated heroin addicts in
relation to methadone treatment. Subst Use Misuse 1998;33:2803–17.
[doi:10.3109/10826089809059352 PMID:9869445](http://dx.doi.org/10.3109/10826089809059352)
38. Galli M, Musicco M; COMCAT Study Group. Mortality of intravenous drug

users living in Milan, Italy: role of HIV-1 infection. AIDS 1994;8:1457–63.
[doi:10.1097/00002030-199410000-00013 PMID:7818817](http://dx.doi.org/10.1097/00002030-199410000-00013)
39. Goedert JJ, Pizza G, Gritti FM, Costigliola P, Boschini A, Bini A et al. Mortality

among drug users in the AIDS era. Int J Epidemiol 1995;24:1204–10.
[doi:10.1093/ije/24.6.1204 PMID:8824864](http://dx.doi.org/10.1093/ije/24.6.1204)
40. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA. Cause-specific mortality

associated with HIV and HTLV-II infections among injecting drug users in
[the USA. AIDS 2001;15:1295–302. doi:10.1097/00002030-200107060-00012](http://dx.doi.org/10.1097/00002030-200107060-00012)
[PMID:11426075](http://www.ncbi.nlm.nih.gov/pubmed/11426075)
41. Golz J, Moll A, Nzimegne S, Klausen G, Schleehauf D. Comparison of

antiretroviral therapy in IVDU and MSM – a retrospective study 1996-2000.
_Suchtmedizin in Forschung und Praxis. 2001;3:25–33._
42. Haarr D, Nessa J. Opioidbehandling av rusmiddelavhengige i en allmennpraksis

[Treatment of opiate-dependent patients in a general practice]. Tidsskr Nor
_[Laegeforen 2007;127:1770–2. PMID:17599124](http://www.ncbi.nlm.nih.gov/pubmed/17599124)_


-----

y y g p p j g


43. Hickman M, Carnwath Z, Madden P, Farrell M, Rooney C, Ashcroft R et al.

Drug-related mortality and fatal overdose risk: pilot cohort study of heroin
users recruited from specialist drug treatment sites in London. J Urban Health
[2003;80:274–87. doi:10.1093/jurban/jtg030 PMID:12791803](http://dx.doi.org/10.1093/jurban/jtg030)
44. Jafari S, Rahimi-Movahgar A, Craib K, Baharlou S, Mathias R. A follow-up

study of drug users in Southern Iran. Addict Res Theory 2010;18:59–70.
[doi:10.3109/16066350902825930](http://dx.doi.org/10.3109/16066350902825930)
45. Jarrin I, Lumbreras B, Ferreros I, Pérez-Hoyos S, Hurtado I, Hernández-Aguado

I. Effect of education on overall and cause-specific mortality in injecting
drug users, according to HIV and introduction of HAART. Int J Epidemiol
[2007;36:187–94. doi:10.1093/ije/dyl231 PMID:17085455](http://dx.doi.org/10.1093/ije/dyl231)
46. Lejckova P, Mravcik V. Mortality of hospitalized drug users in the Czech

[Republic. J Drug Issues 2007;37:103–18. doi:10.1177/002204260703700105](http://dx.doi.org/10.1177/002204260703700105)
47. Liu EW, Wang SJ, Liu Y, Liu W, Chen ZS, Li XY et al. Mortality of HIV infected

clients treated with methadone maintenance treatment in Yili Kazakh
autonomous prefecture. Zhonghua Yu Fang Yi Xue Za Zhi 2011;45:979–84.
[InChinese PMID:22336271](http://www.ncbi.nlm.nih.gov/pubmed/22336271)
48. Lumbreras B, Jarrín I, del Amo J, Pérez-Hoyos S, Muga R, García-de la Hera

M et al. Impact of hepatitis C infection on long-term mortality of injecting
drug users from 1990 to 2002: differences before and after HAART. AIDS
[2006;20:111–6. doi:10.1097/01.aids.0000196164.71388.3b PMID:16327326](http://dx.doi.org/10.1097/01.aids.0000196164.71388.3b)
49. Manfredi R, Sabbatani S, Agostini D. Trend of mortality observed in a cohort of

drug addicts of the metropolitan area of Bologna, North-Eastern Italy, during a
[25-year-period. Coll Antropol 2006;30:479–88. PMID:17058511](http://www.ncbi.nlm.nih.gov/pubmed/17058511)
50. McAnulty JM, Tesselaar H, Fleming DW. Mortality among injection drug

users identified as “out of treatment”. Am J Public Health 1995;85:119–20.
[doi:10.2105/AJPH.85.1.119 PMID:7832249](http://dx.doi.org/10.2105/AJPH.85.1.119)
51. Mezzelani P, Quaglio GL, Venturini L, Lugoboni F, Friedman SR, Des Jarlais

DC. A multicentre study on the causes of death among Italian injecting drug
users. AIDS has overtaken overdose as the principal cause of death. AIDS Care
[1998;10:61–7. doi:10.1080/713612356 PMID:9536202](http://dx.doi.org/10.1080/713612356)
52. Miller CL, Kerr T, Strathdee SA, Li K, Wood E. Factors associated with premature

mortality among young injection drug users in Vancouver. Harm Reduct J
[2007;4:1. doi:10.1186/1477-7517-4-1 PMID:17201933](http://dx.doi.org/10.1186/1477-7517-4-1)
53. Moroni M, Galli M. Causes of death in a cohort of intravenous-drug-users

(IVDUs) recruited in Milan. AIDS Res Hum Retroviruses 1991;7:241–2.
54. Moskalewicz J, Sierosławski J. Umieralność osób uzaleznionych od narkotyków

przyjmowanych w iniekcjach [Mortality of narcotic addicts using injections].
_[Przegl Epidemiol 1996;50:323–32. InPolish PMID:8927745](http://www.ncbi.nlm.nih.gov/pubmed/8927745)_
55. Muga R, Langohr K, Tor J, Sanvisens A, Serra I, Rey-Joly C et al. Survival of HIV
infected injection drug users (IDUs) in the highly active antiretroviral therapy
era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Clin Infect
_[Dis 2007;45:370–6. doi:10.1086/519385 PMID:17599317](http://dx.doi.org/10.1086/519385)_
56. Nyhlén A, Fridell M, Bäckström M, Hesse M, Krantz P. Substance abuse and

psychiatric co-morbidity as predictors of premature mortality in Swedish
drug abusers: a prospective longitudinal study 1970–2006. BMC Psychiatry
[2011;11:122–31. doi:10.1186/1471-244X-11-122 PMID:21801441](http://dx.doi.org/10.1186/1471-244X-11-122)
57. O’Driscoll PT, McGough J, Hagan H, Thiede H, Critchlow C, Alexander ER.

Predictors of accidental fatal drug overdose among a cohort of injection
[drug users. Am J Public Health 2001;91:984–7. doi:10.2105/AJPH.91.6.984](http://dx.doi.org/10.2105/AJPH.91.6.984)
[PMID:11392946](http://www.ncbi.nlm.nih.gov/pubmed/11392946)
58. Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort

of heroin addicts from London clinics: a 22-year follow-up study. Addiction
[1994;89:1299–308. doi:10.1111/j.1360-0443.1994.tb03309.x PMID:7804091](http://dx.doi.org/10.1111/j.1360-0443.1994.tb03309.x)
59. Quan VM, Vongchak T, Jittiwutikarn J, Kawichai S, Srirak N, Wiboonnatakul K

et al. Predictors of mortality among injecting and non-injecting HIV-negative
[drug users in northern Thailand. Addiction 2007;102:441–6. doi:10.1111/j.1360-](http://dx.doi.org/10.1111/j.1360-0443.2006.01709.x)
[0443.2006.01709.x PMID:17298652](http://dx.doi.org/10.1111/j.1360-0443.2006.01709.x)
60. Quan VM, Minh NL, Ha TV, Ngoc NP, Vu PT, Celentano DD et al. Mortality and

HIV transmission among male Vietnamese injection drug users. Addiction
[2011;106:583–9. doi:10.1111/j.1360-0443.2010.03175.x PMID:21054619](http://dx.doi.org/10.1111/j.1360-0443.2010.03175.x)
61. Rahimi-Movahgar A, Khastoo G, Razzaghi EM, Saberi-Zafarghandi MB, Noroozi

AR, Jar-Siah R. Compulsory methadone maintenance treatment of severe cases
of drug addiction in a residential setting in Tehran, Iran: outcome evaluation in
two and six-month follow-up. Payesh 2011;10:503–12.
62. Reece AS. Favorable mortality profile of naltrexone implants for opiate

[addiction. J Addict Dis 2010;29:30–50. doi:10.1080/10550880903435988](http://dx.doi.org/10.1080/10550880903435988)
[PMID:20390697](http://www.ncbi.nlm.nih.gov/pubmed/20390697)
63. Sánchez-Carbonell X, Seus L. Ten-year survival analysis of a cohort of

heroin addicts in Catalonia: the EMETYST project. Addiction 2000;95:941–8.
[doi:10.1046/j.1360-0443.2000.95694110.x PMID:10946442](http://dx.doi.org/10.1046/j.1360-0443.2000.95694110.x)
64. Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting

drug users recently released from prison: database linkage study. BMJ
[1998;316:426–8. doi:10.1136/bmj.316.7129.426 PMID:9492665](http://dx.doi.org/10.1136/bmj.316.7129.426)


65. Solomon SS, Celentano DD, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS

et al. Mortality among injection drug users in Chennai, India (2005–2008). AIDS
[2009;23:997–1004. doi:10.1097/QAD.0b013e32832a594e PMID:19367155](http://dx.doi.org/10.1097/QAD.0b013e32832a594e)
66. Sørensen HJ, Jepsen PW, Haastrup S, Juel K. Drug-use pattern, comorbid

psychosis and mortality in people with a history of opioid addiction. Acta
_[Psychiatr Scand 2005;111:244–9. doi:10.1111/j.1600-0447.2004.00445.x](http://dx.doi.org/10.1111/j.1600-0447.2004.00445.x)_
[PMID:15701109](http://www.ncbi.nlm.nih.gov/pubmed/15701109)
67. Stenbacka M, Leifman A, Romelsjo A. Mortality among opiate abusers in

Stockholm: a longitudinal study. Heroin Addict Rel Clin Prob 2007;9:41–9.
68. Stoové MA, Dietze PM, Aitken CK, Jolley D. Mortality among injecting

drug users in Melbourne: a 16-year follow-up of the Victorian Injecting
[Cohort Study (VICS). Drug Alcohol Depend 2008;96:281–5. doi:10.1016/j.](http://dx.doi.org/10.1016/j.drugalcdep.2008.03.006)
[drugalcdep.2008.03.006 PMID:18434044](http://dx.doi.org/10.1016/j.drugalcdep.2008.03.006)
69. Tait RJN, Ngo HTT, Hulse GK. Mortality in heroin users 3 years after naltrexone

implant or methadone maintenance treatment. J Subst Abuse Treat
[2008;35:116–24. doi:10.1016/j.jsat.2007.08.014 PMID:17931824](http://dx.doi.org/10.1016/j.jsat.2007.08.014)
70. van Haastrecht HJA, van Ameijden EJC, van den Hoek JAR, Mientjes GHC,

Bax JS, Coutinho RA. Predictors of mortality in the Amsterdam cohort of
human immunodeficiency virus (HIV)-positive and HIV-negative drug users.
_[Am J Epidemiol 1996;143:380–91. doi:10.1093/oxfordjournals.aje.a008752](http://dx.doi.org/10.1093/oxfordjournals.aje.a008752)_
[PMID:8633622](http://www.ncbi.nlm.nih.gov/pubmed/8633622)
71. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM et al. Effectiveness of

highly active antiretroviral therapy among injection drug users with late-stage
human immunodeficiency virus infection. Am J Epidemiol 2005;161:999–1012.
[doi:10.1093/aje/kwi133 PMID:15901620](http://dx.doi.org/10.1093/aje/kwi133)
72. Vlahov D, Wang C, Ompad D, Fuller CM, Caceres W, Ouellet L et al.;

Collaborative Injection Drug User Study. Mortality risk among recent-onset
injection drug users in five US cities. Subst Use Misuse 2008;43:413–28.
[doi:10.1080/10826080701203013 PMID:18365941](http://dx.doi.org/10.1080/10826080701203013)
73. Zábranský T, Csémy L, Grohmannová K, Janíková B, Brenza J. Mortality of cohort

of very young injecting drug users in Prague, 1996–2010. Cent Eur J Public
_[Health 2011;19:152–7. PMID:22026292](http://www.ncbi.nlm.nih.gov/pubmed/22026292)_
74. Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, Vlahov D et al. Impact of

HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS
[1994;8:345–50. doi:10.1097/00002030-199403000-00008 PMID:8031512](http://dx.doi.org/10.1097/00002030-199403000-00008)
75. Zhang L, Ruan YH, Jiang ZQ, Yang ZN, Liu SZ, Zhou F et al. [A 1-year prospective

cohort study on mortality of injecting drug users]. Zhonghua Liu Xing Bing Xue
_[Za Zhi 2005;26:190–3. PMID:15941506](http://www.ncbi.nlm.nih.gov/pubmed/15941506)_
76. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee

SA. Reference Group to the UN on HIV and Injecting Drug Use. Global
epidemiology of injecting drug use and HIV among people who inject
[drugs: a systematic review. Lancet 2008;372:1733–45. doi:10.1016/S0140-](http://dx.doi.org/10.1016/S0140-6736(08)61311-2)
[6736(08)61311-2 PMID:18817968](http://dx.doi.org/10.1016/S0140-6736(08)61311-2)
77. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R et al.

Reference Group to the UN on HIV and Injecting Drug Use. HIV prevention,
treatment and care for people who inject drugs: A systematic review of global,
[regional and country level coverage. Lancet 2010;375:1014–28. doi:10.1016/](http://dx.doi.org/10.1016/S0140-6736(10)60232-2)
[S0140-6736(10)60232-2 PMID:20189638](http://dx.doi.org/10.1016/S0140-6736(10)60232-2)
78. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance versus no

opioid replacement therapy for opioid dependence. Cochrane Database Syst
_[Rev 2009;3:CD002209. PMID:19588333](http://www.ncbi.nlm.nih.gov/pubmed/19588333)_
79. _Declaration of Commitment on HIV/AIDS – United Nations special session on HIV/_

_AIDS. In: Twenty-sixth special session of the General Assembly of the United_
Nations. 25-27 June 2001. New York, United States of America; 2001.
80. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee

SA et al. Reference Group to the UN on HIV and Injecting Drug Use. Global
epidemiology of injecting drug use and HIV among people who inject
[drugs: a systematic review. Lancet 2008;372:1733–45. doi:10.1016/S0140-](http://dx.doi.org/10.1016/S0140-6736(08)61311-2)
[6736(08)61311-2 PMID:18817968](http://dx.doi.org/10.1016/S0140-6736(08)61311-2)
81. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D.

Evidence for the effectiveness of sterile injecting equipment provision
in preventing hepatitis C and HIV transmission among injecting drug
[users: a review of reviews. Addiction 2010;105:844–59. doi:10.1111/j.1360-](http://dx.doi.org/10.1111/j.1360-0443.2009.02888.x)
[0443.2009.02888.x PMID:20219055](http://dx.doi.org/10.1111/j.1360-0443.2009.02888.x)
82. Tilson H, Aramrattana A, Bozzette S. Preventing HIV infection among injecting

_drug users in high-risk countries: an assessment of the evidence. Washington:_
Institute of Medicine; 2007.
83. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M.

Prevention of HIV infection for people who inject drugs: Why individual,
structural, and combination approaches are required. Lancet 2010;376:285–
[301. doi:10.1016/S0140-6736(10)60742-8 PMID:20650522](http://dx.doi.org/10.1016/S0140-6736(10)60742-8)
84. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction

[2005;100:1823–31. doi:10.1111/j.1360-0443.2005.01259.x PMID:16367983](http://dx.doi.org/10.1111/j.1360-0443.2005.01259.x)
85. Kulinskaya E, Morgenthaler S, Staudte R. Meta analysis: a guide to calibrating

_and combining statistical evidence. Wiley-Interscience; 2008._


-----

